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Pediatric liver transplantation provides life-saving therapy to children with end-stage liver 
disease but more widespread use is greatly hindered by the availability of deceased 
donor organs. Newer surgical techniques that use partial grafts (i.e., “technical-variant 
transplantation), including living-donor liver transplantation (LDLT) and split liver 
transplantation (SLT), allow for opportunities to increase the supply of organs and 
reduce waitlist mortality and morbidity.  
 
To understand the potential benefit of these technical-variants grafts, we first conducted 
an analysis of patient and graft survival using the Scientific Registry of Transplant 
Recipients (SRTR) to determine if there was a change in outcomes over time associated 
with use of these newer surgical procedures. We subsequently explored outcomes for 
children on the liver transplant waitlist using SRTR and determined how waitlist 
outcomes, including living donation, vary based on sociodemographic characteristics. In 
order to better understand why African Americans and individuals on public assistance 
use LDLT at lower rates, we conducted a survey of potential barriers for parents of 
children with ESLD or transplant recipients including an assessment of their 
understanding of LDLT, its process, risks and harms. Finally, we performed an analysis 
of effect modifiers for SLT using SRTR data to identify which candidates had worse 
relative outcomes with SLT compared to WLT, and which candidates had similar 
outcomes irrespective of graft type.  
 
We determined that, for pediatric (<18 years) candidates from 2002-2009, post-
transplant mortality for whole liver transplant (WLT, 95%) was similar to LDLT (96%; P = 
0.2) but worse for SLT (92%; P = 0.002). Since 2010, mortality for WLT (95%) was 
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worse than LDLT (98%; P = 0.01) and similar to SLT (95%; P = 0.7). We also showed 
that individuals were half as likely to use LDLT if they were on public assistance (sHR: 
0.430.520.63) or African American (sHR: 0.410.560.75). Our survey demonstrated that many 
individuals in the pediatric liver transplant community are not aware of the steps for 
LDLT evaluation (28% unaware), who to ask (10%), that the procedure is covered by 
insurance (31%), and what the impact might be on the donor’s work (24%) or health 
(25%). These barriers were generally seen in higher frequencies for individuals that are 
often disadvantaged (e.g., beneficiaries of public insurance). Finally, we identified 
subgroups of individuals that experienced higher graft failure following SLT compared to 
WLT including individuals with non-BA congenital cholestasis (aHR: 1.102.093.97) or 
metabolic disease (aHR: 1.061.572.28), as well as children between 10-35 kg (aHR: 
1.101.371.70).  
 
Collectively, this research provides updated information regarding outcomes for these 
procedures, identifies barriers towards their application, and suggests potential clinical or 
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Chapter 1. Introduction  
 
Pediatric end-stage liver disease (ESLD) results from multiple congenital and acquired 
diseases and is universally fatal without intervention. Children with ESLD invariably 
experience severe disability and profound impairments in nutrition, cognitive 
development, immunity, coagulation and quality of life.1–3 Over the last 25 years, liver 
transplantation has been utilized as a life-saving treatment for over 15,000 children in 
the United States with ESLD, thereby providing these individuals with decades of high 
quality of life.2,4 Outcomes are generally very good, with 5-year graft survival of 82% for 
recipients of deceased-donor grafts and 86% for recipients of living-donor grafts.5  
 
Liver transplantation is greatly hindered by a scarcity of available organs.5 Since 2002, 
the United States has allocated livers using a quantitative assessment of an individual’s 
pre-transplant mortality risk derived from the Pediatric End-stage Liver Disease (PELD) 
score for individuals <12 years, and the Model for End-stage Liver Disease (MELD) 
score for individuals 12 years but this strategy means that most individuals are 
extremely sick before they receive a new liver, and in some instances they will die while 
waiting. 6–8 Children less than 1 year are especially vulnerable to organ shortages and 
have higher mortality on the waitlist compared to adults (12.4 vs 10.0 deaths per 100 
waitlist years) given the rarity of suitable deceased donors (i.e., appropriately-sized 
individuals without medical comorbidities) for children. This imbalance between the 
supply of available livers and its demand means that as many as 10% of children on the 
waitlist die while waiting for an offer.  
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In addition to waitlist mortality, organ shortage prolongs the time that waitlist candidates 
experience substantial morbidity. Approximately 700 new pediatric candidates are added 
to the waitlist every year; the need for organs has been steadily increasing, while the 
number of transplants, 500-600 per year, has been relatively constant.5 Over the last 
decade, adults and pediatric candidates waiting for organs have higher allocation 
scores, and, at least among adults, individuals with higher allocation scores have 
significantly increased morbidity.6 This is likely to be so among children as well. 
 
One exciting solution to organ shortage is the use of technical-variant grafts such as 
living-donor liver transplantation (LDLT), during which a friend or relative donate a 
portion of his/her liver.9 Since this technique was first reported in 1989, a number of 
potential benefits have been noted.10,11 LDLT provides the opportunity to transplant 
patients before they begin to experience substantial morbidity. Recipients of organs from 
biologically-related individuals may also have a higher likelihood of being able to 
discontinue immunosuppression and would be able to avoid or mitigate the 
complications of long-term immunosuppression such as chronic kidney disease and 
diabetes. Even though LDLT is a more complex surgery than whole liver transplantation 
(WLT), and may have higher rates of vascular thrombosis or biliary stricture, overall graft 
failure is similar, as was described in 2007 in a large registry study of pediatric 
recipients.12  
 
Split-liver transplantation (SLT) is a second type of technical-variant surgery that 
involves transplanting a single deceased-donor liver into two recipients, with a larger 
portion going typically to an adult and a smaller portion going to a child. Given that 
nearly 5,000 adult deceased-donor livers are available for transplant into adult recipients 
every year, increasing use of SLT with these organs would have a dramatic impact on 
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organ shortage for the 700 children that are waiting for a liver transplant and would lead 
to substantial reductions in waitlist morbidity and mortality. Outcomes following SLT 
have been inferior to WLT for pediatric recipients due to higher rates of vascular 
thrombosis and biliary stricture as well as graft failure, although recent data are not 
available.12 Despite the problem of waitlist mortality and morbidity that results from 
decreased organ availability, only 10% of pediatric transplant recipients are transplanted 
using a living-donor and 15% are transplanted with a split-liver.5  
 
The overarching goal of this dissertation is to better understand how the principal 
outcomes in liver transplantation, patient and graft survival, are influenced by graft type 
and to learn more about outcomes with technical-variant graft surgery. In Chapter 2, we 
use data from the Scientific Registry for Transplant Recipients (SRTR) to evaluate 15-
year trends in graft and patient survival for WLT, LDLT, and SLT. Our hypothesis is that 
outcomes for LDLT and SLT, while initially reported to be inferior to WLT, have 
improved. If so, greater use of technical-variant grafts will provide an opportunity to 
substantially increase the organ supply while decreasing waitlist morbidity and mortality. 
 
Chapters 3 and 4 directly address barriers to access of LDLT. There is strong evidence 
of health disparities between individuals from different racial/ethnic groups awaiting 
transplantation, with use of living-donation being substantially lower among African-
American and Hispanic adults.13,13 First, we analyze SRTR to determine if waitlist 
outcomes (i.e., deceased-donation, living-donation, and death) for pediatric liver 
transplant candidates vary by race/ethnicity. Our hypothesis was that children from racial 
and ethnic minority groups on the waitlist for liver transplants are less likely to utilize 
LDLT, and that they may have higher rates of waitlist mortality. 
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Second, we developed a survey for parents of children that are waiting or who have 
received a liver transplant to further explore barriers to LDLT. Literature from adult 
kidney transplant patients has identified a number of important barriers to living-donation 
including inadequate patient information, poor provider communication, diminished 
social network, and mistrust of the medical community.14–16 Evidence from studies of 
adult transplant candidates/recipients supports that these barriers are more frequent 
among individuals with specific sociodemographic characteristics including African 
Americans, and individuals with lower income and lower educational attainment. Our 
hypothesis was that these barriers exist in pediatric liver transplantation as well, and that 
these barriers are more frequent in groups that are underserved or with decreased 
resources.   
 
In Chapter 5, we address the potential to expand the supply of organs through greater 
use of SLT by further exploring which patients are appropriate candidates SLT. Using 
the SRTR, we studied individuals that received either a WLT or SLT and explored 
whether the relationship between graft type and graft failure was modified by specific 
donor, recipient, or surgical characteristics. We hypothesized that the relationship 
between graft type and graft failure would vary depending on recipient characteristics 
and that there are subgroups of pediatric recipients having equivalent risk of graft failure 
irrespective of whether they receive an SLT or WLT. Individuals with these 
characteristics may be optimal candidates for SLT. This information will guide clinical 
decision-making, and may inform policy decisions surrounding liver allocation as well.  
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Chapter 2. Fifteen-year Trends in Pediatric Liver 
Transplants: Split, Whole Deceased, and Living Donor 
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Background: To evaluate changes in patient and graft survival for pediatric liver 
transplant recipients since 2002, and to determine if these outcomes vary by graft type 
(whole liver transplant (WLT), split liver transplant (SLT), and living-donor liver transplant 
(LDLT)). 
 
Methods: We evaluated patient and graft survival among pediatric liver-only transplant 
recipients the PELD/MELD system was implemented using the Scientific Registry of 
Transplant Recipients.  
 
Results: From 2002-2009 to 2010-2015, survival for SLT improved at 30 days (94% vs 
98%; P<0.001), and at 1 year improved for SLT (89% to 95%; P<0.001) and LDLT (93% 
to 98%; P=0.002); there was no change in survival for WLT at either 30 days (98% in 
both; P=0.7) or 1 year (94% vs 95%; P=0.2). Risk of early death with SLT was 2.14-fold 
higher in 2002-2009 (adjusted hazard ratio (aHR) vs WLT: 1.472.143.12) but this risk 
disappeared in 2010-2015 (aHR: 0.651.131.96), representing a significant improvement 
(P=0.04). Risk of late death following SLT was similar in both time periods (aHR 2002-
2009: 0.871.141.48; aHR 2010-2015: 0.560.881.37). LDLT had similar risk of early death (aHR 
2002-2009: 0.491.032.14; aHR 2010-2015: 0.260.742.10) and late death (aHR 2002-2009: 
0.520.831.32; aHR 2010-2015: 0.170.441.11). Graft loss was similar for SLT (aHR: 0.931.091.28) 
and was actually lower for LDLT (aHR: 0.530.710.95).  
 
Conclusion: In recent years, outcomes following use of technical-variant grafts are 
comparable to whole grafts, and may be even be superior for LDLT. Greater use of 
technical-variant grafts might provide an opportunity to increase organ supply without 




Liver transplantation provides life-saving therapy for children with end-stage liver 
disease.1,2 Unfortunately, successful pediatric transplantation is hindered by a scarcity of 
suitable livers.18 Under the current PELD (Pediatric End-stage Liver Disease) and MELD 
(Model for End-stage Liver Disease) system, organs are allocated to patients based on 
their probability of death within 90 days while awaiting transplant. This strategy means: 
(1) the pre-transplant course for most individuals is associated with significant morbidity, 
hospitalization, and costs; (2) delays in transplantation exacerbate long-term 
impairments in cognition and growth; and (3) in some instances, children die on the 
waitlist.1,2,6  
 
Use of technical-variant donation, including split liver transplantation (SLT) and living-
donor liver transplantation (LDLT), represents a potential solution to the organ shortage.7 
Given that approximately 6,000 whole livers are used for adult recipients each year, SLT 
for children represents an exciting opportunity to improve organ supply, shorten waitlist 
times, and decrease pre-transplant morbidity and mortality. Evidence from studies of 
adult recipients suggest that outcomes following SLT have improved in recent years and 
may have achieved parity with WLT.19 However, reports on outcomes for pediatric 
recipients following technical-variant donation, and in particular SLT, are 
conflicting.12,20,21  
 
Given these inconsistent findings, the purpose of our analysis was to use a large 
national registry to better understand the impact of allograft type on patient and graft 
survival for pediatric liver transplant recipients in the most recent era. Furthermore, we 
sought to assess whether the association between allograft type and outcomes following 
transplantation have changed over time period and whether these effects vary by follow-
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up time. Finally, we wanted to better understand which factors are associated with graft 




This study used data from the SRTR. The SRTR data system includes data on all 
donors, waitlisted candidates, and transplant recipients in the U.S., submitted by the 
members of the Organ Procurement and Transplantation Network (OPTN) and has been 
described elsewhere.22 The Health Resources and Services Administration, U.S. 
Department of Health and Human Services, provides oversight to the activities of the 
OPTN and SRTR contractors. The interpretation and reporting of these data are the 
responsibility of the author(s) and in no way should be seen as an official policy of, or 
interpretation by, the SRTR or the U.S. Government. 
 
Study Population 
We identified 5715 pediatric (age < 18 years), liver-only, first transplant recipients who 
received an organ between March 1, 2002 (i.e., after implementation of the PELD/MELD 
system) and December 31, 2015. Additionally, people were excluded for the following 
reasons: listed as live donor whole liver (n = 10), missing weight (n = 1), missing cold 
ischemia time (n = 395; 6% of eligible individuals). No donor organs were obtained from 
executed prisoners or other institutionalized persons. Individuals were defined as having 
a split liver transplant (SLT) if they received a portion of a deceased donor graft, 
irrespective of whether the organ was used by one or two recipients as evidence from 
other studies suggest comparable graft and patient survival, and even potentially 
comparable biliary strictures and vascular thromboses.12,19  We compared demographic 
(e.g. age, sex, race, and insurance status) and clinical (e.g., weight, PELD/MELD, and 
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diagnosis) characteristics between pediatric recipients of SLT, whole liver transplantation 
(WLT) and living donor liver transplantation (LDLT) using 2 tests for categorical 
variables and analysis of variance (ANOVA) for continuous variables.  
 
Unadjusted Patient and Graft Survival  
We calculated patient and graft survival at 30-days and 1-year following SLT, WLT, or 
LDLT, and compared survival between allograft types using Kaplan-Meier curves and 
log-rank tests. Patient death was identified using the SRTR, which is linked to the Social 
Security Master File and confirmed through clinician report. Graft failure was identified 
as any reported graft failure or death (i.e., “all cause graft loss”). Recipients were 
censored upon re-transplantation or multi-organ transplantation (e.g., liver-kidney).  
 
Adjusted Patient and Graft Survival  
We used Cox proportional hazards models to characterize the association between 
allograft type and graft and patient survival after adjustment for recipient weight at 
transplant, recipient age at transplant, gender, race/ethnicity, underlying disease, 
allocation PELD/MELD at transplant, status 1 designation, donor age, cold ischemia time 
(CIT), and insurance type; sensitivity analysis with laboratory PELD/MELD and 
exception status were also performed and did not influence findings. Additional 
sensitivity analysis with transplant region was assessed using shared frailty.23 The 
decision to include these specific variables in the final model for multivariable regression 
was derived from associations between covariates with risk factors and the outcome in 
both the published literature as well as statistical tests (e.g., chi-square, ANOVA) within 
this cohort.  
 
Trends Over Time 
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To characterize changes in unadjusted patient and graft survival over time, 30-day and 
1-year survival between allograft types were further stratified by time period of 
transplantation (i.e., 2002-2009 vs 2010-2015). We used an interaction term analysis to 
determine whether the association between allograft type and adjusted patient and graft 
survival varied over time period.  
 
Time-varying Hazard of Patient Survival 
We tested whether the hazard associated with patient survival following SLT, LDLT, and 
WLT varied over follow-up time using a time-binned analysis and estimated the hazard 
associated with each allograft type within the first 30 days post-transplant (i.e., early) 
and after the first 30 days post-transplant (i.e., late).  
 
Statistical Analysis 
All statistical tests used a two-sided  of 0.05. Categorical variables were compared 
using a chi-square test and continuous variables were compared using ANOVA. 
Confidence intervals are reported using the method of Louis and Zeger, as previously 
reported.24 All analyses were performed using STATA 14.0 (College Station, TX, USA). 
This study was approved by the Institutional Review Board of Johns Hopkins University 




Among the 5715 children who underwent liver transplantation, 3428 (60%) received a 
WLT, 1626 (28.5%) a SLT, and 661 (11.6%) a LDLT (Table 1 online). SLT and LDLT 
recipients were more likely to be under 2 years and 10 kg (P < 0.001 for both age and 
weight). African Americans were less likely than Caucasians to undergo LDLT, and more 
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likely to receive a whole graft (P < 0.001). LDLT recipients were more likely to have had 
biliary atresia (P < 0.001). The donor age for nearly all individuals receiving a living 
donor was 18-50 years of age, whereas WLT recipients were more likely to have donors 
age 0-17 years (P < 0.001). PELD/MELD score at transplant was lower in LDLT (P < 
0.001), while SLT recipients were more likely to be status 1 than WLT and LDLT 
recipients (P < 0.001). The mean cold ischemia time (CIT) was shortest for LDLT (P < 
0.001). LDLT recipients were more likely to have private insurance and SLT recipients 
were more likely to have public insurance (P < 0.001).  
 
Trends in Allograft Volume 
From 2002-2009 to 2010-2015, the frequency of transplants was similar for WLT (60% 
for both), SLT (29% and 28%) and LDLT (11% and 12%) (P = 0.6). Frequency of 
reduced SLT (i.e., “cut-down”), where only one portion was used, was the same for both 
periods (13.2% and 13.6%). Among 104 centers performing any type of liver transplant, 
66 (63%) centers performed at least 1 SLT over the entire study period, and 8 (8%) 
performed at least 1 SLT each year. Fifty-seven (55%) centers performed at least 1 
LDLT over the entire study period, and 4 (4%) centers performed at least 1 LDLT per 
year. 
 
Short-term Patient Survival 
Since the PELD/MELD system was implemented in 2002, the unadjusted 30-day patient 
survival across all allograft types was 97%, and was significantly lower in SLT compared 
to WLT (96% vs 98%; P < 0.001), while survival for LDLT and WLT was similar (98% for 
both; P = 0.4; Table 2). The relative impact of allograft type on short-term survival varied 
by time period (Figure 1). From 2002-2009, survival following SLT was worse than WLT 
(94% vs 98%; P < 0.001) whereas from 2010-2015, no significant difference was 
 12 
observed (98% for both; P = 0.96). Outcomes following LDLT were similar to WLT in 
both 2002-2009 (97% vs 98% P = 0.96) and 2010-2015 (99% vs 98%; P = 0.2). Only 
SLT demonstrated an improvement in short-term survival (94% in 2002-2009 vs 98% in 
2010-2015; P < 0.001). In an adjusted model, SLT was associated with a 2.14-fold 
higher risk of early death (i.e., within 30 days) from 2002-2009 (aHR: 1.472.143.12; Table 
3) while there was no increased risk of early death from 2010-2015 (aHR: 0.651.131.96), 
representing a significant improvement (P for interaction = 0.04). Adjustment for 
transplant region did not change inferences. Short-term survival following LDLT was the 
same in both time periods (aHR vs WLT in 2002-2009: 0.491.032.14; aHR vs WLT in 2010-
2015: 0.260.742.10).   
 
Long-term Patient Survival 
Patient survival at 1 year was 94% for all pediatric recipients over the study period and 
significantly lower for SLT compared to WLT (92% vs 95%; P = 0.002), but similar for 
LDLT and WLT (96% vs 95%; P = 0.2). The relative impact of allograft type on short-
term survival varied by time period. From 2002-2009, survival following SLT was worse 
than WLT (89% vs 94%; P < 0.001), whereas no significant difference was observed 
from 2010-2015 (95% for both; P = 0.2). From 2002-2009, survival following LDLT was 
similar to WLT (93% vs 94%, P = 0.6), but from 2010-2015, survival was higher for LDLT 
(98% vs 95%; P = 0.01). Survival at 1 year improved for both SLT (89% in 2002-2009 
and 95% in 2010-2015; P < 0.001) and LDLT (93% in 2002-2009 and 98% in 2010-
2015; P = 0.002) but did not improve for WLT (94% in 2002-2009 and 95% in 2010-
2015; P = 0.2). Compared to WLT, the long-term (i.e., after 30 days) risk of death was 
similar in both time periods for SLT (aHR in 2002-2009: 0.871.141.48; aHR in 2010-2015: 




Overall unadjusted 30-day graft survival was 93% (Table 4 online; Figure 2 online). Only 
SLT showed significant improvement from 2002-2009 to 2010-2015 (90% vs 93%; P = 
0.01) whereas no improvement was seen in WLT (92% vs 93%; P = 0.1) or LDLT (94% 
vs 95%; P = 0.6). Graft survival at 1 year improved for SLT (85% vs 90%; P = 0.002) and 
LDLT (89% vs 94%; P = 0.03) but not WLT 89% vs 90%; P = 0.14). In an adjusted 
model, the association between allograft type and graft survival did not vary by time 
period (P > 0.05 for interaction coefficients) and thus, overall estimates are reported 
instead. Additionally, the hazard of graft failure was proportionally constant throughout 
the follow-up period and therefore early and late graft failure were not evaluated 
separately. Compared to WLT, SLT was not associated with an increased risk of graft 
failure (aHR: 0.931.091.28), while LDLT was associated with a lower risk of graft failure 
(aHR: 0.530.710.95; Table 5). Overall graft survival improved from 2002-2009 to 2010-2015 
(aHR: 0.650.740.86).  
 
Additional Risk Factors for Death and Graft Failure 
In a multivariable model, several other characteristics were associated with both death 
and graft failure (Table 6 online). Acute hepatic necrosis, malignancy, and status 1 
designation were associated with increased death and graft loss, as was public 
insurance and donor age >50 years. Recipient race/ethnicity, weight, and allocation 
score at transplant were not associated with death or graft failure. Although recipient age 
was not associated with death, children 2-12 years had lower graft loss than children <2 




Transplant region was associated with allograft type in both 2002-2009 (P < 0.001) and 
2010-2015 (P < 0.001). Inclusion of transplant region into the model did not affect 
inferences on patient. For example, similar to the model without region, the 30-day risk 
of death for SLT was increased in 2002-2009 (aHR: 1.482.163.13) but not increased in 
2010-2015 (aHR: 0.681.182.04) representing a significant improvement (P = 0.04). 
Similarly, inclusion of region into the model did not influence risk of graft loss (aHR for 
SLT: 0.941.101.29; aHR for LDLT: 0.550.741.00). 
 
DISCUSSION 
In this national study examining trends in pediatric liver transplantation since the 
implementation of the PELD/MELD system, several important findings were evident with 
respect to the relationship between allograft type and patient/graft survival. First, while 
overall outcomes have improved, these can be largely attributed to improvements in 
early outcomes following SLT, as well as to improvements in long-term outcomes 
following SLT and LDLT; outcomes following WLT have been largely unchanged since 
the current PELD/MELD system was implemented. Second, poor outcomes for SLT 
were initially due to increased early death but this problem is no longer evident such that 
risk of early death in SLT has decreased, and is similar to, WLT. Finally, graft survival for 
LDLT appears to be superior to WLT. Collectively, these findings suggest that the 
increasing experience with technical-variant grafts such as SLT and LDLT have 
coincided with improved patient and graft survival. 
 
Our analysis also identifies several important risk factors for death and graft failure in 
this large cohort including notable findings that better outcomes may be seen in biliary 
atresia, as well as lower rates of graft failure in children between 2-12 years. 
Additionally, although all race/ethnic groups had comparable outcomes, higher rates of 
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death and graft loss were seen in individuals with public insurance. These findings are 
consistent with other challenges facing individuals in the pediatric liver transplant 
community with public insurance such as higher rates of waitlist mortality, and lower 
likelihood of obtaining exception points.25,26  
 
Reports on the impact of allograft type in pediatric liver transplantation have been 
conflicting. The SPLIT consortium of 44 pediatric centers examined a range of outcomes 
on recipients from 1995-2006 and found increased graft failure in SLT, but not LDLT, 
when compared with WLT in an unadjusted model.12 These authors also reported higher 
rates of complications requiring either surgical revision in both SLT and LDLT compared 
with WLT. A second study from the SPLIT consortium showed increased death and graft 
loss for both technical-variant grafts.27 A large single-center study of recipients between 
1993-2006 similarly found a higher risk of mortality and graft failure in SLT, but not 
LDLT.20 Other studies derived from the UNOS and SRTR registries prior to the 
implementation of PELD/MELD have shown a general tendency for SLT to have worse 
patient and graft survival, whereas LDLT may have superior or equivalent outcomes 
compared with WLT.28,29 At the same time, some studies have suggested that allograft 
type does not affect outcomes. Austin et al. looked at outcomes in UNOS from as early 
as 1987-2004 and showed no difference in patient and graft survival by allograft type, 
but this finding may be driven by relatively poor outcomes in this cohort from all 
transplants in the early years of the cohort. For example, the authors report an overall 1-
year patient survival of 83% compared with 94% in our study.10 Finally, in the most 
recent study from SRTR that evaluated patient and graft survival in a limited cohort of 
children under 12 years old from 2002-2004, there was no variability in outcomes by 
allograft type.21  
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Our finding that overall patient and graft survival following pediatric liver transplantation 
have improved over time is broadly consistent with other studies.30,31 One large study 
derived from the United Network for Organ Sharing (UNOS) database from 1995-2010 of 
children showed that patient and graft survival improved from 1995-2000 to 2006-2010, 
but saw similar results between 2001-2005 and the end of the study period.30 This study 
was limited to children under 2 years old that received a whole or deceased split graft, 
and because it spanned the implementation of PELD/MELD, it was not possible to adjust 
for the score or status 1 designation and authors used ICU and ventilator status instead. 
They also tested for interaction between eras and allograft status and showed a trend 
toward improved relative hazard following SLT compared with WLT, but the interaction 
between era and allograft type was not significant for patient or graft survival. Here, we 
demonstrated overall improvement since PELD/MELD was implemented and across all 
pediatric age groups. Furthermore, we showed significant improvement in the most 
recent transplant period (i.e., 2010-2015) such that outcomes following SLT are now 
similar to WLT.  
 
An important consideration when discussing increased adoption of SLT is the impact on 
the adult recipient who might otherwise get a whole graft, especially as split liver 
transplantation has been seen as contributing to a donor risk index in some, but not all, 
adult studies.32,33 A recent study of the UNOS database looking at adult SLT recipients 
reported similar findings that patient and graft survival have improved over time and are 
now similar to WLT.19 At the same time, increased vascular and biliary complications 
continue to be reported in technical-variant donation relative to WLT and one important 
limitation of our study was that we were unable to explore these additional 
complications.27,34,35 While use of these grafts will increase the organ supply, allow for 
earlier transplantation, and potentially decrease total costs, at the same time, 
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complications from these grafts are likely to be associated with longer length of stay and 
greater cost in the perioperative period.6,35,36 Given the current need to optimize 
outcomes and reduce costs (i.e., increase value), the decision to use these organs by 
transplant teams, and to advocate for greater use through policy, will require a better 
understanding of the frequency of these complications and how these complications 
impact care from a number of perspectives.37 Nonetheless, some centers have 
incorporated practices where SLT is prioritized, and have been able to achieve the 
competing goal of good long-term outcomes alongside the benefits of increased organ 
supply.38  
 
Another limitation of our study was that it was derived from an observational cohort as 
opposed to an experimental study. While the finding that overall outcomes have 
improved over time should be expected, it is difficult to know whether the decision by the 
transplant team to perform a specific type of transplant is a reflection of their assessment 
of the patient’s disease severity, surgical experience, or some other factor; if SLT was 
only performed when the patient was perceived to be relatively stable, this decision 
might influence the observed outcomes. One advantage of our study is that it is 
conducted exclusively in the PELD/MELD era, and we adjusted for the score at 
transplant as well as exception status, a well-validated tool for assessing medical 
severity. Consequently, the relative effects that were seen in the multivariable model that 
adjusted for score and exception status should account for the impact of disease 
severity. But while it is possible that the improvement seen in SLT can be attributed to 
unmeasured or residual confounding of disease severity that coincides with a shift in 
clinical practice and decision making, our evidence nonetheless suggests that a group of 
children can do well with SLT, and that more research should be performed to identify 
the specific patient, donor, and surgical characteristics that yield good outcomes. 
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Finally, it should be noted that there can be errors in reporting from studies derived from 
national registries, such as patients being incorrectly classified as dead or with graft 
failure. However, these errors should be minimal, if they exist at all, given that SRTR 
verifies death with the Social Security Master File and that graft failure must be 
accurately identified in the registry in order for a patient to receive a new liver.  
 
Given shortages in organ supply, there is continued interest and effort in identifying 
additional opportunities to expand the supply, including use of extended criteria donors, 
donation after cardiac death, and technical-variant donation.7,39–41 Children may be 
particularly vulnerable to decreased supply, with a recent report suggesting that nearly 
half of all children that died on the waitlist had not received a single offer of a liver, with a 
median offer number of one.25 Size mismatch was identified in nearly one third of 
patients as a reasons offers were not accepted, though nearly half may have actually 
been an appropriate size, suggesting the potential for greater use of split transplantation 
in reducing waitlist mortality. Our national study of over 5000 pediatric liver transplant 
recipients provides strong evidence that allograft type no longer predicts patient and 
graft survival in this population. These findings have the potential to substantially 
influence policy for allocation of deceased organs to children in need. Given that children 
compose a relatively small percentage of people on the national waitlist, increased use 
of SLT might provide an optimal way to increase the supply for children, without placing 





Table 1: Demographic and Clinical Characteristics by Transplant Type 
Characteristic WLT SLT LDLT P**  
Total 3428 (60.0) 1626 (28.5) 661 (11.6)  
Recipient Age          
 <2 years 1328 (38.7) 983 (60.5) 418 (63.2) <0.001 
 2-5 years 592 (17.3) 355 (21.8) 95 (14.4)  
 5-12 years 709 (20.7)  225 (13.8) 87 (13.2)  
 12-18 years 799 (23.3)  63 (3.9) 61 (9.2)  
Recipient Weight     
  <10 kg 1119 (32.6) 832 (51.2) 361 (54.6) <0.001 
  10-35 kg 1296 (37.8) 691 (42.5) 218 (33.0)  
  >35 kg 1013 (29.6) 103 (6.3) 82 (12.4)  
Female  1769 (51.6) 812 (49.9) 331 (50.1) 0.5 
Race/ethnicity      
 Caucasian, non-Hispanic 1793 (52.3) 796 (49.0) 389 (58.9) <0.001 
 African American 594 (17.3) 243 (15.4) 74 (11.2)  
 Hispanic 736 (21.5) 431 (26.5) 142 (21.5)  
 Asian 193 (5.6) 99 (6.1) 43 (6.5)  
 mixed/other 112 (3.3) 50 (3.1) 13 (2.0)  
Disease     
 biliary atresia 1195 (34.9) 710 (43.7) 341 (51.6) <0.001 
 metabolic disease 578 (16.9) 231 (14.2) 50 (7.6)  
 acute hepatic necrosis 451 (13.2) 222 (13.7) 81 (12.3)  
 tumor 314 (9.2) 159 (9.8) 31 (4.7)  
 miscellaneous 890 (26.0) 304 (18.7) 158 (23.9)  
Donor Age      
 0-17 years 2890 (84.3) 968 (59.5) 1 (0.2) <0.001 
 18-50 years 468 (13.7) 628 (38.6) 642 (97.1)  
 >50 years 70 (2.0) 30 (1.8) 18 (2.7)  
PELD/MELD at transplant* 23.6 (8.9) 24.9 (8.6) 21.0 (11.8) <0.001 
Status 1 1089 (31.8) 614 (37.8) 144 (21.8) <0.001 
Cold Ischemia Time* (hour) 7.3 (3.5) 7.3 (2.9) 2.8 (5.3) <0.001 
Insurance     
  public  1697 (46.9) 898 (55.2) 217 (32.8) <0.001 
 private 1608 (46.9) 685 (42.1) 413 (62.5)  
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 mixed/other 123 (3.6) 43 (2.6) 31 (4.7)  
Time Period     
 2002-2009 1842 (53.7) 890 (54.7) 346 (52.3) 0.6 
 2010-2015 1586 (46.3) 736 (45.3) 315 (47.7)  
* mean (SD) 





Table 2: 30-day and 1-year Unadjusted Patient Survival  
 Overall 2002-2009 2010-2015  
  Survival  P  Survival  P  Survival  P  P* 
30-day           
   all allografts 0.97   0.96   0.98  0.004 
  WLT 0.98  -- 0.98  --  0.98  -- 0.7 
  SLT 0.96  <0.001  0.94  <0.001  0.98  0.96  <0.001 
  LDLT 0.98  0.4  0.97  0.96  0.99 0.2 0.2 
1-year        
 all allografts 0.94  0.93  0.96  <0.001 
 WLT 0.95 -- 0.94 -- 0.95 -- 0.2 
 SLT 0.92 0.002 0.89 <0.001 0.95 0.7 <0.001 
 LDLT 0.96 0.2 0.93 0.6 0.98 0.01 0.002 
WLT (whole liver transplantation); SLT (split liver transplantation); LDLT (living-donor liver 
transplantation) 
P* represents test of significance from log-rank tests for difference in survival for a specific 




Table 3: Adjusted Hazard Ratio (aHR) for Risk of Death  
 2002-2009 2010-2015  
 aHR (95% CI) P aHR (95% CI) P P* 
Within 30 days      
  WLT -- -- -- -- -- 
  SLT 1.472.143.12  <0.001  0.651.131.96   0.7  0.04  
  LDLT 0.491.032.14 0.9  0.260.742.10   0.65  0.6  
After 30 days      
 WLT -- -- -- -- --  
 SLT 0.871.141.48 0.4 0.560.881.37 0.6 0.3 
 LDLT 0.520.831.32 0.4 0.170.441.11 0.08 0.2 
CI (confidence interval); WLT (whole liver transplantation); SLT (split liver 
transplantation); LDLT (living-donor liver transplantation) 
P* tests whether the aHR for SLT and LDLT, each compared to WLT, varies by 
time period (i.e., interaction). 
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Table 4: 30-day and 1-year Unadjusted Graft Survival   
 Overall 2002-2009 2010-2015  
  Survival  P  Survival  P  Survival  P  P* 
30-day           
   all allografts 0.93   0.92   0.93   0.1  
  WLT 0.93  -- 0.93  --  0.93  -- 0.9  
  SLT 0.92  0.06  0.90  0.005  0.93 0.7 0.01  
  LDLT 0.94 0.2  0.94   0.6 0.95 0.2  0.6  
1-year        
 all allografts 0.89  0.87  0.91  <0.001  
 WLT 0.89 -- 0.89 -- 0.90 --  0.14 
 SLT 0.87 0.02 0.85 0.004 0.90 0.9  0.002 
 LDLT 0.91 0.2 0.89 0.9 0.94 0.05  0.03 
WLT (whole liver transplantation); SLT (split liver transplantation); LDLT (living-donor 
liver transplantation) 
P* represents test of significance using log-rank test of difference in survival for a 
specific allograft type from 2002-2009 to 2010-2015  
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Table 5: Adjusted Hazard Ratio (aHR) for Graft Failure  
 Graft Failure 
Allograft   aHR (95% CI) P  
WLT   -- -- 
SLT   0.931.091.28   0.3  
LDLT 0.530.710.95    0.02 
CI (confidence interval); WLT (whole liver transplantation); 
SLT (split liver transplantation); LDLT (living-donor liver 
transplantation) 
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Table 6: Additional Risk Factors for Death and Graft Failure 
 Death  Graft Failure 
Characteristic aHR P aHR P 
Disease     
  Biliary Atresia -- -- -- -- 
 Metabolic Disease 0.851.171.61 0.3 0.891.121.41 0.3 
 Acute Hepatic Necrosis 1.201.672.31 0.002 1.181.511.93 0.001 
 Malignancy 2.202.974.02 <0.001 1.491.892.41 <0.001 
 Other/unknown 1.511.922.45 <0.001 1.301.561.86 <0.001 
Recipient race/ethnicity     
 Caucasian, non-Hispanic -- -- -- -- 
 African American 0.961.211.52 0.1 0.921.101.30 0.3 
 Hispanic 0.780.961.20 0.7 0.740.871.03 0.1 
 Asian 0.610.911.35 0.6 0.570.781.06 0.1 
 Mixed/other 0.580.951.57 0.8 0.610.891.29 0.5 
Recipient weight     
 <10 kg -- -- -- -- 
 10-35 kg 0.690.931.26 0.7 0.730.921.15 0.5 
 >35 kg 0.580.951.57 0.8 0.620.911.33 0.6 
Recipient age     
 <2 years -- -- -- -- 
 2-5 years 0.530.751.04 0.09 0.600.770.99 0.04 
 5-12 years 0.581.851.23 0.4 0.540.710.95 0.02 
 12-18 years 0.701.171.95 0.5 0.660.971.44 0.9 
Insurance     
 Private -- -- -- -- 
 Public 1.201.441.72 <0.001 1.081.241.41 0.002 
 Other/missing 0.540.941.61 0.8 0.520.791.20 0.3 
Allocation score at transplant 0.991.001.01 0.5 0.991.001.00 0.3 
Status 1 1.001.231.51 0.05 1.021.191.61 0.03 
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Cold ischemia time (hour) 0.991.011.03 0.2 1.001.011.03 0.07 
Donor age     
 <18 years -- -- -- -- 
 18-50 years 0.911.151.44 0.2 0.981.181.41 0.07 
 >50 years 1.171.791.2.73 0.007 1.742.383.24 <0.001 
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Background: African Americans and other minorities are known to face barriers to 
health care influencing their access to organ transplantation but it is not known whether 
these barriers exist among pediatric liver transplant waitlist candidates. We sought to 
determine whether outcomes on the waitlist (i.e., mortality, deceased donor liver 
transplantation (DDLT), and living-donor liver transplantation (LDLT)) varied by 
race/ethnicity. 
 
Methods: National registry data were studied to estimate the race/ethnicity-specific risk 
of waitlist mortality, DDLT and LDLT in children (<18 years) waitlisted between March, 
2002 and March, 2015.  
 
Results: There was no evidence of racial/ethnic disparities in waitlist mortality. 
Compared to Caucasians, LDLT varied by race/ethnicity, with only 6.7% African 
Americans and 10.3% Hispanic children receiving LDLT compared with 12.4% 
Caucasian, 13.3% Asian, and 9.4% mix/other children. In an adjusted Cox proportional 
hazards model, African Americans were half as likely as Caucasians to use LDLT 
(hazard ratio (HR): 0.410.550.73) but had similar use of DDLT (HR: 0.981.061.16). In a model 
that considered mortality, DDLT, and LDLT as competing risks, African Americans had 
significantly reduced incidence of LDLT (subhazard ratio (sHR): 0.410.560.75) compared to 
Caucasians, but increased use of DDLT (sHR: 1.061.161.26).  
 
Conclusion: Compared to Caucasian children, African-American children are less likely 
to use LDLT but have higher rates of DDLT and similar survival on the waitlist. Additional 
research is necessary to understand the clinical and socioeconomic factors contributing 
to lower utilization of LDLT among African-American children awaiting transplantation.  
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INTRODUCTION 
Since implementation of the Pediatric End-stage Liver Disease (PELD) and Model for 
End-stage Liver Disease (MELD) system in 2002, liver transplantation has provided life-
saving therapy for over 5,000 children in the United States.42 Outcomes after 
transplantation in children are excellent, with 1-year and 5-year survival reported to be 
95% and 85%, respectively.17 Furthermore, increasing experience with newer surgical 
techniques in recent years, such as living-donor liver transplantation (LDLT), may yield 
outcomes that are superior to whole liver transplantation while allowing for shorter 
waitlist periods and a reduction in associated pre-transplant morbidity.21,43  
 
There is strong evidence that health disparities exist between individuals from different 
racial/ethnic groups that are waitlisted for organ donation, and these disparities are likely 
to apply to children with end-stage liver disease (ESLD) as well.13,14 First, African-
American adults with ESLD are less likely to be referred for liver transplantation and are 
more likely to die while awaiting transplantation.13 Second, use of LDLT is significantly 
reduced in African-American adults.44 Third, racial/ethnic disparities exist in access for 
children with end-stage kidney disease awaiting transplantation, as well as in their use of 
living donation.45 Fourth, Hsu et al. report that nearly one third of children on the liver 
transplant waitlist are ultimately transplanted through use of exception points, for which 
use differs by race/ethnicity.46,47  
 
Given the evidence that racial/ethnic disparities exist among adults awaiting organ 
donation and children awaiting kidney donation, we evaluated whether these disparities 
exist for children awaiting liver transplantation. Specifically, we hypothesize that African-
American children have lower rates of living donation for liver transplantation and that 
the lower rate cannot be explained by geographic consolidation around centers that do 
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not offer LDLT. Furthermore, given the lower use of exception points for African 
Americans, the possibility exists that this group is disadvantaged with respect to waitlist 




This study used data from the Scientific Registry of Transplant Recipients (SRTR). The 
SRTR data system includes data on all donors, waitlisted candidates, and transplant 
recipients in the U.S., submitted by the members of the Organ Procurement and 
Transplantation Network (OPTN) and has been described elsewhere.22 The Health 
Resources and Services Administration (HRSA), U.S. Department of Health and Human 
Services, provides oversight to the activities of the OPTN and SRTR contractors. The 
interpretation and reporting of these data are the responsibility of the author(s) and in no 




This study included pediatric (age less than 18 years), liver-only transplant candidates 
who were initially listed between March 1, 2002 (i.e., implementation of PELD/MELD), 
and October 31, 2014. Data were administratively censored on March 31, 2015. 
Candidates listed for re-transplantation or listed as Status 1A were excluded from 
analysis.  
 
Candidate Race/Ethnicity  
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Candidate race/ethnicity was classified as Caucasian/White (i.e., Caucasian non-
Hispanic), African American/Black, Hispanic/Latino (i.e., Caucasian Hispanic), Asian, 
and mixed/other.  
 
Hazard of Waitlist Outcomes by Candidate Race/Ethnicity Group 
Waitlisted candidates were followed until they received a DDLT (either a whole liver 
transplant or segmental graft from a deceased donor), LDLT, or died. Death was defined 
by the date that an individual was removed from the waitlist due to death, medical 
unsuitability or refusal to transplant for declining health, or deteriorating condition, 
regardless of whether the candidate was active or not on the waitlist. The hazards of 
DDLT, LDLT, and mortality while on the waitlist were examined individually using Cox 
proportional hazards regressions to model the cause-specific hazards in unadjusted and 
adjusted models. In Cox proportional hazard models, individuals are followed from time 
entry (i.e., listing) to the time that they have an event (e.g., transplant, death), are lost-to-
follow-up, or are administratively censored. In considering one of the three specific 
events, candidates were censored when either of the other two outcomes occurred (for 
example, in considering mortality, candidates were censored once they received either a 
DDLT or LDLT).  This method allowed us to identify candidate-specific risk factors, 
including race/ethnicity and other potential biologic associations with waitlist outcomes 
independent of the effects of organ allocation. 
 
Subhazard of Waitlist Outcomes Accounting for Organ Allocation 
In order to evaluate the association between race/ethnicity and outcomes due to the 
allocation system, DDLT, LDLT, and mortality were considered together in a competing 
risk regression.48 In a competing risk regression, instead of censoring candidates when 
an alternate outcome occurs, the subhazards account for the fact that the candidate is at 
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risk of more than one outcome and that these outcomes compete with each other. For 
example, if a candidate receives a LDLT, they are no longer at risk of receiving a DDLT. 
 
Sensitivity Analysis of Centers Performing LDLT  
To verify that any reduced rate of LDLT among African Americans (or any race/ethnic 
group) was not due to geographic consolidation away from centers where LDLT was not 
available, a  sensitivity analysis was performed on centers that had performed ≥1 LDLT 
per year during the study period on pediatric recipients. 
 
Statistical Analysis 
Categorical variables were compared using a chi-square test. Comparison of continuous 
variables was made using Wilcoxon rank-sum test. Cox proportional hazard models 
were used to compare the hazard ratio (HR) for each outcome, as well as the subhazard 
ratio (sHR) in a competing risk model. All analyses were adjusted for primary diagnosis 
(i.e., biliary atresia, inborn error of metabolism, tumor, and other), weight, ABO blood 
type, status 1B, insurance status, and year. Age was excluded from the multivariable 
analysis because there was evidence of collinearity with weight (variance inflation factor 
>2.5), which would lead to overfitting of the model. Analyses were also adjusted using a 
patient’s calculated or laboratory PELD/MELD score; based on prior research, exception 
points were considered a mediator between race/ethnicity and outcomes and therefore 
should not be included from adjustment in a multivariable model 46. PELD was used for 
children on the waitlist before they turned 12 years old, and MELD was used for children 
on the waitlist who were older than 12 years. Because an individual’s weight and 
PELD/MELD score change over time, these variables were treated as time-varying 
variables, meaning that the specific time that an individual spent at each level 
contributed separately to the risk of a given outcome. The multivariable model also 
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analyzed the change in the allocation score for every 5 points. There were no missing 
data for any variables in the model. The proportional hazards assumption was checked 
using complementary log-log curves. Statistical significance was tested using a two-
sided  of 0.05. Confidence intervals are reported using the method of Louis and Zeger, 
as previously reported.24,49 All analyses were performed using STATA 14.0 (College 
Station, TX, USA). This study was approved by the Institutional Review Board of Johns 




We studied 7,355 children on the liver waitlist including 1,184 (16.1%) African American, 
3,927 (53.4%) Caucasian, 1,629 (22.1%) Hispanic, 390 (5.3%) Asian, and 225 (3.1%) 
children of mixed/other race/ethnicity (Table 1). Biliary atresia (BA) was the indication for 
transplant in 2,398 (32.6%) registrants, whereas 3,869 (52.6%) were listed for reasons 
other than BA, metabolic disease, or malignancy. The median (interquartile range (IQR)) 
calculated PELD/MELD score at listing was 15 (6-27). Among waitlisted children, 4,532 
(61.6%) ultimately received a DDLT and 558 (7.6%) received a LDLT, whereas 631 
(8.6%) children died on the waitlist and 1,634 (22.2%) were still on the waitlist at the end 
of the study.  
 
Characteristics by Race/Ethnicity 
Compared to Caucasians, African Americans had lower median age at listing (14 vs. 20 
months; pairwise P = 0.002) and at removal (22.2 vs. 31.2 months; P = 0.01; Table 2) 
alongside lower median weight at listing (8.7 vs. 10.9 kg; pairwise P < 0.001) and at 
removal (10.2 vs. 12.0 kg; P < 0.001). At the same time, the median allocation score was 
higher for African Americans compared to Caucasians at listing (15 vs.10; pairwise P < 
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0.001) and at removal (17 vs.14; P < 0.001). ABO blood type and disease category also 
varied across all races (groupwise P < 0.001). African Americans were less likely to be 
granted exception points compared to Caucasian (30.7% vs 41.3%; pairwise P < 0.001), 
Asian (40%; P = 0.001), or Hispanic (35.2%; P = 0.017) children on the waitlist. Among 
those who ultimately received a DDLT, there was no difference in the use of whole liver 
transplantation compared to split liver transplantation by African-American and 
Caucasian recipients (split: 75.2 vs. 74.3%; pairwise P > 0.05). 
 
Predictors of Outcomes on Waitlist  
Compared to Caucasians, African Americans had significantly higher 1-year unadjusted 
cumulative incidence of DDLT (65.3% vs. 63.8%; competing risk model P = 0.04), lower  
LDLT (4.9% vs. 8.8%; P < 0.001) and similar mortality (8.5% vs. 8.3%; P > 0.05; Table 
3). Hispanics had higher mortality than Caucasian non-Hispanics (10.1% vs 8.3%; P = 
0.02), lower use of LDLT (7.0 vs 8.8; P = 0.047) and similar use of DDLT (64.1% vs 
63.8%; P > 0.05). In an adjusted Cox proportional hazard model, African Americans 
were half as likely as Caucasians to receive LDLT (HR: 0.410.550.73) compared with 
Caucasians (Table 4a), while having similar rate of mortality (HR: 0.791.001.26) and DDLT 
(HR: 0.981.061.16). In an adjusted model that that considered the competing risk of DDLT, 
LDLT, and mortality, African Americans continued to show decreased use of LDLT (sHR: 
0.410.560.75) compared with Caucasians but had corresponding higher risk of DDLT (sHR: 
1.061.161.26; Table 4b). Subhazard of mortality in a competing risk did not vary by 
race/ethnicity. Analysis of data that excluded inactive person time did not change the 
findings.  
 
In the competing risk model, for every 5 points higher in allocation score (e.g., 35 vs. 30, 
15 vs. 10), there was greater risk of mortality (sHR: 1.942.032.12), LDLT (sHR: 1.251.311.38) 
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and DDLT (sHR: 1.231.261.28). However, compared to an allocation score of 40, status 1B 
was associated with lower mortality (sHR: 0.270.350.45) and lower use of LDLT (sHR: 
0.200.330.54) but greater use of DDLT (sHR: 1.331.531.77). Children ≤10 kg also had higher 
likelihood of death (sHR: 1.72 2.13 2.64), DDLT (sHR: 1.05 1.14 1.22) and LDLT (sHR: 1.77 2.23 
2.82) compared with children weighing 15 kg or more. Individuals with blood type A (sHR: 
1.241.331.42) and AB (sHR: .521.742.00) had greater use of DDLT compared to individuals 
with blood type O, but did not have higher rate of mortality. Individuals with public 
insurance had lower use of LDLT (sHR: 0.450.540.65), higher use of DDLT (sHR: 
1.021.081.15) and higher mortality (sHR: 1.161.381.54). The probability of dying on the waitlist 
decreased each year from 2002 onward (sHR: 0.940.960.99), while the probability of 
getting transplanted using DDLT (sHR: 1.021.031.04) or LDLT (sHR: 1.021.041.07) increased.  
 
Center Impact 
Among the 106 centers that performed a pediatric liver transplant over the study period, 
89 centers performed at least one LDLT (84%), and 29 (27%) performed 1 LDLT per 
year. For individuals transplanted at centers performing 1 LDLT per year, the likelihood 




To the best of our knowledge, our study is the first to look at potential disparities for all 
outcomes (i.e., DDLT, LDLT, and death) for children awaiting liver transplantation since 
the adoption of the PELD/MELD system, and we demonstrate that disparities do exist for 
waitlisted children. Specifically, African Americans are half as likely as Caucasians to 
use LDLT. Furthermore, this observation was independent of insurance status, a factor 
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that is well-known to correlate with, but not thoroughly account for, socioeconomic status 
(SES). Therefore, other aspects of an individual’s SES may provide additional 
explanation for reduced use of LDLT in African Americans. Our findings also suggest 
that these variations are not due to consolidation of African Americans around centers 
that don't offer LDLT. These data also indicate that African Americans correspondingly 
receive DDLT at increased rates compared with Caucasians, an observation that could 
not be explained by a lack of availability of LDLT at those centers. Finally, Hispanic 
children had higher mortality compared to Caucasian non-Hispanic children in an 
unadjusted analysis, but risk of mortality between these groups was similar after 
adjustment in the multivariable model.  
 
While the probability of waitlist mortality does not vary across race/ethnic groups, the 
use of exception points is associated with reduced risk of mortality, and their use has 
been shown to correlate with race/ethnicity.47,50 Specifically, a recent publication by Hsu 
et al. noted that, while exception score request were made for 34% of waitlisted children 
and granted for 90% of these requests, the rate of requests for non-Caucasian children 
throughout their time on the waitlist was significantly lower than for Caucasian children.46 
Not surprisingly, these exception points were associated with increased likelihood of 
transplantation. However, the authors found a lower, but not statistically significant, rate 
of transplantation for non-Whites, whereas we demonstrate a higher rate of DDLT for 
African Americans. This discordance is likely to be explained in that our analysis 
separates out living and deceased donors and that the lower use of LDLT among African 
Americans correlates with the higher use of DDLT in this group. Additionally, the earlier 
study did not report on racial differences in mortality, whereas our study suggests that 
the overall mortality is the same between groups.  
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We found that African Americans, compared to Caucasians, have younger age and 
lower weights at listing and removal from the list (i.e., death or transplant) while 
simultaneously they have higher allocation scores at listing and removal. It is not clear if 
these observations are the consequence of some bias on the part of providers, if the 
natural history varies by race such that African American children progress more rapidly 
toward ESLD, or if race is correlated with other socioeconomic determinants of 
Presently, there is little evidence to suggest that the natural history of biliary atresia, the 
indication for nearly half of all liver transplants, varies by race/ethnicity.51,52 Similarly, 
there is no evidence that age at Kasai, an important predictor of outcomes in biliary 
atresia, is associated with race. At the same time, listing individuals when they have 
more severe disease, as evidenced by higher PELD/MELD score and lower weight, may 
make LDLT less feasible and may be associated with worse outcomes after 
transplantation.  
 
The evaluation of the association between race/ethnicity and outcomes for individuals 
awaiting liver transplantation has been inconclusive, and research has been largely 
limited to studies of adult candidates that vary from children with respect to their 
underlying disorders. Reid et al. looked at outcomes for adult waitlist candidates in the 
pre-MELD era and found higher rates of mortality and lower rates of transplantation in 
African-American candidates compared to Caucasians.53 However, two studies from the 
post-MELD era found equivalent likelihood of death and transplantation for African 
Americans and Caucasians.54,55 Finally, a study of children with BA, the most common 
pediatric cause of ESLD, did not identify race/ethnicity as a risk factor for waitlist 
mortality but also did not specifically look at rates of LDLT.51  
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Our finding that African-American children waitlisted for transplant are half as likely to 
use LDLT is new, but not surprising. Several investigators have identified a range of 
barriers to transplantation experienced by racial/ethnic minorities awaiting 
transplantation, and have suggested these barriers are multifactorial.13,14 For example, a 
study of adult liver transplant patients that collected data on the evaluation of potential 
living donors noted that African-American patients had less inquiries per patient for LDLT 
than Caucasian patients.44 Although this study of waitlisted adult patients did not have 
additional socioeconomic data of potential living donors or recipients, reports from the 
kidney transplant literature show a similar decrease in the rates of living donation among 
African Americans and these have been attributed to financial concerns, reluctance to 
ask family members, distrust of the medical community, and lack of health literacy or 
understanding of the process.14,44,56,57 One limitation from our study is that the only 
socioeconomic status variable recorded in SRTR is insurance status, which does not 
fully represent a true surrogate. Consequently, we are not able to explain how varying 
rates of LDLT by race may be due in part to variations in socioeconomic status such as 
education and cultural literacy or frequency of single-income household.    
 
Although pre-transplant mortality was comparable for African Americans and 
Caucasians, lower rates of LDLT in African Americans may have significant effects on 
both their pre-transplant morbidity as well as their post-transplant morbidity and 
mortality. Specifically, studies of adult candidates awaiting transplant have demonstrated 
that patients undergoing LDLT are transplanted at lower MELD scores and consequently 
have lower pre-transplant length of hospital stay, length of stay in the intensive care unit, 
and lower hospital costs.6 Similar discrepancies in pre-transplant morbidity likely occurs 
among children awaiting transplantation. At the same time, living donation may be 
associated with improved patient and graft survival compared to deceased 
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donation.21,43,58 Therefore, lower rates of LDLT among African-American children 
awaiting transplantation has implications that extend beyond access to treatment for 
ESLD, but to long-term morbidity and mortality as well.   
 
It is clear that increasing the supply of available organs will positively affect quality of life 
for children awaiting transplantation, and earlier transplantation would likely have a 
positive impact on long-term outcomes following transplantation as well. Living donation 
is one important method of increasing this supply. While our study identifies African-
American children as being listed at higher PELD/MELD scores and less likely to use a 
living donor, our study is limited in its ability to identify the root cause of these disparities. 
Do physicians advocate for this approach at different rates depending on race/ethnicity? 
Are the patients’ families unaware LDLT is an option? Is the decision to pursue LDLT or 
DDLT influenced heavily by the family’s available resources and ability to interrupt a 
source of income while care is being provided to both the sick child and the donor? Or 
do other variables such as health literacy or differences in culture account for reduced 
rates of living donation? Depending on the reason for decreased rates of LDLT in 
African-American children, there may be solutions that would yield higher rates of living 
donation to the benefit of African Americans and all waitlisted children.  
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Table 1: Characteristics of pediatric waitlist registrants  
Characteristic No. (%) 
Age in months (median, IQR)   
 at listing  16 (7-101) 
 at end of follow-up*  25.5 (10.3-114.6) 
Weight in kg (median, IQR)   
 at listing 9.7 (6.6-24.8) 
 at end of follow-up  11 (7.3-26.3) 
Female  3,726 (50.7) 
Race/ethnic group  
 African American 1,184 (16.1) 
 Caucasian  3,927 (53.4) 
 Hispanic 1,629 (22.1) 
 Asian 390 (5.3) 
 mixed/other 225 (3.1) 
Blood type  
 O 3,648 (49.6) 
 A 2,467 (33.5) 
 B 952 (13) 
 AB 288 (3.9) 
Disease   
 biliary atresia 2,398 (32.6) 
 metabolic disease 211 (2.9) 
 malignancy 877 (11.9) 
 other 3,869 (52.6) 
Outcome  
 death 631 (8.6) 
 living-donor liver transplant  558 (7.6) 
 deceased donor liver transplant 4,532 (61.6) 
  whole liver transplant 3,304 (72.9) 
 split/partial 1,228 (27.1) 
 censored 1,634 (22.2) 
PELD/MELD score (median, IQR)   
 at listing 15 (6-27) 
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 at end of follow-up  27 (15-40) 
Status 1B 323 (4.4) 
Private insurance 3,392 (46.1) 





Table 2: Patient characteristics by race/ethnicity  
 Caucasian African  
American 
Hispanic    Asian mixed/other P*  
Number 3,927 1,184  1,629 390 225  
Age in months 
(median, IQR) 
      
 at listing 20 (7-121) 14 (7-102.5) 14 (6-70) 13 (7-74) 10 (6-30) <0.001 













Weight in kg 
(median, IQR) 
      

























Female (%) 49.6 52 53.3 47.4 48.9 >0.05 
Blood type (%)       
 O 46.3 47.8 60.4 40.8 53.8 <0.001 
 A 39.3 25 28.2 25.6 31.1  
 B 10.4 21.8 8.8 29.7 11.5  
 AB 4 5.4 2.6 3.9 3.6  
Years of follow-














      
  at listing  10 (6-18) 15 (7-21) 11 (6-20) 12 (6-20) 15 (6-22) <0.001 
  at end of 
follow-up 
14 (6-22) 17 (9-23) 15 (6-23) 13 (6-21) 18 (8-27) <0.001 
Exception 
points (%) 
41.3 30.7 35.2 40 28.9 <0.001 
Status 1B (%) 4.3 4 4.8 3.6 6.7 >0.05 
Disease (%)       
 biliary atresia 29.7 36.5 32.3 46.7 40 <0.001 
  metabolic 3.6 1.3 3 1.8 0.9  
  malignancy 12.8 7.5 12.8 13.1 11.5  
  other 53.9 54.7 51.9 38.4 47.6  
Private 
insurance (%) 
59.4 30.9 24.1 58.5 33.3 <0.001 
*Groupwise P values 













Caucasian non-Hispanic 8.3 -- 63.8 -- 8.8 -- 
African American 8.5 >0.05 65.3 0.04 4.9 <0.001 
Hispanic 10.1 0.02 64.1 >0.05 7 0.047 
Asian 7 >0.05 68 >0.05 10.1 >0.05 
mixed/other 14.3 0.001 64.9 >0.05 5.7 >0.05 
DDLT = decreased donor liver transplant; LDLT = living donor liver transplant 




Table 4: Estimates of Hazard Ratios (HR) by Outcome 
 Mortality DDLT LDLT 
Race/ethnic group    
  Caucasian non-Hispanic -- -- -- 
  African American 0.791.001.26 0.981.061.16 0.410.550.73 
  Hispanic 0.941.141.39 0.920.991.08 0.730.921.15 
  Asian 0.711.061.59 0.931.061.21 0.670.941.33 
  mixed/other 0.971.412.06 0.790.941.11 0.410.701.20 
Allocation score (per 5 points) 
increase) 
1.942.032.12 1.231.261.28 1.251.311.38 
Status 1B (to PELD/MELD 40) 0.270.350.45 1.331.531.77 0.200.330.54 
Diagnosis    
  biliary atresia -- -- -- 
  metabolic disease 0.260.701.92 1.001.181.39 0.340.621.15 
  malignancy 0.490.741.13 1.041.161.30 0.540.781.12 
  other 1.752.162.66 0.640.690.74 0.350.430.52 
Weight    
  ≥15 kg -- -- -- 
  10-15 kg 1.191.572.06 0.850.931.02 1.141.522.03 
  ≤10 kg 1.722.132.64 1.051.141.22 1.772.232.82 
Blood type    
  O -- -- -- 
  A 0.931.111.33 1.241.331.42 0.911.091.31 
   B 0.961.221.54 1.001.101.21 0.811.051.36 
  AB 0.390.701.25 1.521.742.00 0.380.691.22 
Insurance    
  private -- -- -- 
  public/other 1.161.381.54 1.021.081.15 0.450.540.65 
Year (2002 reference) 0.940.960.99 1.021.031.04 1.021.041.07 
DDLT = deceased donor liver transplant; LDLT = living donor liver transplant 
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Table 5: Estimates of Subhazard Ratios (sHR) by Outcome 
 Mortality DDLT LDLT 
Race/ethnic group    
  Caucasian non-Hispanic -- -- -- 
  African American 0.740.941.19 1.061.161.26 0.410.560.75 
  Hispanic 0.891.101.36 0.910.991.07 0.710.901.13 
  Asian 0.570.871.34 0.901.041.20 0.650.911.28 
  mixed/other 0.921.372.06 0.770.931.13 0.390.661.14 
Allocation score (per 5 point increase) 1.601.69 1.77 1.06 1.081.11 1.071.131.19 
Status 1B (to PELD/MELD 40) 0.230.320.44 1.802.122.50 0.210.340.54 
Diagnosis    
  biliary atresia -- -- -- 
  metabolic disease 0.27 0.74 2.06 1.03 1.18 1.36 0.31 0.57 1.03 
  malignancy 0.50 0.81 1.33 1.15 1.29 1.45 0.40 0.57 0.81 
  other 2.47 3.09 3.86 0.65 0.69 0.75 0.38 0.46 0.56 
Weight    
  ≥15 kg -- -- -- 
  10-15 kg 1.091.441.89 0.77 0.84 0.92 1.15 1.52 2.01 
  ≤10 kg 1.23 1.53 1.91 0.79 0.86 0.93 1.45 1.81 2.27 
Blood type    
  O -- -- -- 
  A 0.770.931.12 1.161.241.33 0.760.921.11 
   B 0.911.171.49 0.941.041.15 0.730.951.24 
  AB 0.250.450.82 1.571.832.14 0.270.480.85 
Insurance    
  private -- -- -- 
  public/other 1.101.331.53 1.041.111.19 0.430.520.63 
Year (2002 reference) 0.910.930.95 1.031.041.05 1.001.031.06 







Table 6: Estimates of Subhazard Ratio (sHR) for Living Donor Liver 
Transplantation (LDLT) for Individuals Waitlisted at Centers Performing 3 
LDLT   
Race/ethnic group LDLT 
  Caucasian non-Hispanic -- 
  African American 0.380.530.72  
  Hispanic  0.720.921.16 
  Asian  0.701.001.42 
  mixed/other  0.430.741.28 
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Background: Children receiving a living-donor liver transplant (LDLT) have superior 
post-transplant outcomes but this procedure is only used for 10% of transplant 
recipients. Better understanding about barriers toward LDLT and the sociodemographic 
characteristics that influence these variables would help to inform strategies to increase 
its use.  
 
Methods: Using a convenience sample, we conducted an online, anonymous survey of 
parents and caregivers for children who are awaiting, or have received, a liver transplant 
regarding their knowledge and attitudes about the procedure.  
 
Results: The survey was completed by 217 respondents including 27 (12%) parents of 
children that are currently being evaluated/waitlisted and 190 (88%) parents of children 
that have been transplanted. We found that while 97% of respondents understood that 
an individual could donate a portion of their liver, only 72% knew the steps in the 
process, and 69% understood that the donor surgery was covered by the recipient’s 
insurance. Individuals with public insurance were significantly less likely than those with 
private insurance to know the steps for living donor evaluation (44% vs 82%; P < 0.001). 
Only 38% of respondents correctly understood that outcomes following living donation 
are better than deceased donation, whereas 46% thought the outcomes were the same, 
17% thought living donation was worse, and 9% of respondents had no opinion about 
relative outcomes for each surgery. Respondents with public insurance were less likely 
than those with private insurance to know someone who had been a living donor (44% 
vs 56%; P = 0.005) as were individuals without a college degree compared to those with 
a college degree (64% vs 85%; P = 0.007). Nearly all respondents generally trusted their 
healthcare team. Among respondents, 82% believed they were well-informed about 
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LDLT but individuals with public insurance were significantly less likely to feel well-
informed about LDLT (67% vs 87%; P = 0.03) and to understand how the donor surgery 
might impact donor work/time-off (44% vs 81%; P = 0.001).  
 
Conclusion: Substantial gaps exist in parental understanding about LDLT, including the 
process of living-donor evaluation, its potential benefits, and complications. Greater 
emphasis on addressing identified barriers to access of LDLT, especially communication 
to individuals with fewer resources, such as those receiving public insurance, will be 




Liver transplantation is the definitive cure for children with end-stage liver disease and 
has provided life-saving therapy to more than 5,000 children in the United States over 
the past decade.42 Outcomes following transplant are excellent with an overall 1-year 
patient survival of 93% and 1-year graft survival of 89%.59 Living-donor liver 
transplantation (LDLT), although more surgically complex than whole liver 
transplantation (WLT), has superior outcomes with a 96% 1-year patient survival and 
94% 1-year graft survival. This finding is particularly exciting because LDLT provides an 
opportunity to transplant children before they develop substantial pre-transplant 
morbidity and to mitigate the risk of dying on the waitlist. Despite these benefits, only 
10% of pediatric liver transplant candidates are transplanted using a living donor and its 
use has been stable over recent years.5,59,60  
 
Purnell et al. created a framework that describe how access to care in living donation is 
influenced by patient/donor, provider, healthcare system, and community factors.61 Much 
of what is known about barriers in access to living-donor transplantation has been 
observed within the context of adult kidney transplantation. First, studies of adult kidney 
transplant patients suggest that candidates may lack information about living donation 
including benefits to the recipient and the potential risk/safety for the donor.14–16,62 
Second, evidence exists from this population that some patients and potential donors 
may have general mistrust of the medical community and therefore seek to avoid an 
additional surgery.63  Third, candidates and their families may have, or perceive they 
have, limited social networks or individuals that they feel comfortable approaching about 
living donation.64–66 Fourth, there may be social or financial limitations on an individual’s 
ability to pursue living donation.67–70 And fifth, transplant teams may variably support the 
option of living donation for their patients, such that the option is not offered at their 
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center or even region. Socioeconomic characteristics have also been shown in liver 
transplantation to influence access of LDLT and further promote health disparities in 
both adult and pediatric candidates.71–75 For example, children on public insurance are 
half as likely to use a living donor as children with private insurance, and African-
American children are half as likely as Caucasian children to be transplanted with a 
living donor.  
 
To better understand barriers toward access of LDLT for pediatric candidates, and to 
explore how these barriers may be influenced by sociodemographic characteristics, we 
surveyed online Facebook communities of parents and caregivers for children who are 
awaiting, or have received, a liver transplant. This information could then help to identify 





The study population was a convenience sample of parents of children (<18 years) who 
are currently being evaluated for a liver transplant, waitlisted for transplant, or recipients 
of a liver transplant. Parents who were >18 years of age and able to speak English were 
eligible to participate.  
 
Recruitment Strategy 
Respondents were recruited over Facebook using several mechanisms from February to 
April, 2018. First, respondents were recruited through Liver Space “app,”, a Facebook-
integrated app that is free and available on the Apple and Android stores and that has 
been described elsewhere.76 Briefly, Liver Space provides users with several functions 
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such as the ability to receive the latest news of interest to the user, ask-an-expert 
questions, locate other members of the community to arrange meetups, and track 
laboratory results. At the beginning of the study period, Liver Space had 450 users 
including 38% parent/caregivers, 51% patients and 11% healthcare providers. Among 
users, 23% were listed as transplant recipients. Second, respondents were recruited 
through the Liver Space “page” on Facebook, which had 982 followers at the start of the 
recruitment period. Third, two paid Facebook campaigns directed toward adults with 
interest in liver issues were promoted in a campaign that had a combined reach of 2,099 
people. And finally, Facebook posts were shared over five large groups, each with 
greater than 1,000 members and are focused on pediatric liver disease or liver 
transplantation. Respondents were informed that participation was voluntary, and they 
would not be reimbursed for completing the study. The anonymous study was exempted 
by the Institutional Review Board of the Johns Hopkins University School of Medicine.  
 
Instrument 
The survey was developed by study team members including individuals with expertise 
in transplant hepatology, clinical research, survey development, health services 
research, epidemiology, and health disparities research. The anonymous, quantitative 
survey consisted of 44 questions including 25 questions addressing knowledge and 
attitudes about transplantation that used a 5-point Likert scale (i.e., “strongly agree,” 
“somewhat agree,” “neutral,” “somewhat disagree,” and “strongly disagree”). Questions 
assessed the following potential barriers: (1) knowledge about the living donor 
evaluation process, including an understanding that a family member or friend can 
donate a part of their liver, the steps for evaluation, and that the cost of donor surgery 
and follow-up is covered by recipient’s insurance; (2) knowledge about outcomes 
following living donation as compared to WLT; (3) size and nature of an individual’s 
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social network, including whether they knew someone that been evaluated, or served, as 
a living donor; the number of people with whom they discuss health-related issues; and 
their perception of how it might affect relationships; (4) trust in the medical community, 
including whether they trust their doctor to do the right thing, typically agree with their 
doctor, and felt their questions were answered; and (5) their perception about provider 
communication as it relates to concerns about outcomes for the donor, outcomes for the 
recipient, and concerns about the burden associated with donation. 
 
Respondents were also asked additional questions that further characterized their 
sociodemographic background including: (1) insurance status, i.e., public (exclusively 
Medicaid or public insurance connected to income) versus private or mixed 
public/private; (2) education level; (3) marital status, i.e., single versus married or living 
with partner; (4) employment status, i.e., fully employed, part-time employed, 
homemaker, other; (5) number of working adults in the house; and (6) race/ethnicity. 
Their technological “fluency” (i.e., frequency and use of digital devices) was also 
assessed. They survey was pilot tested for grammar and clarity by patients. The survey 
was created and distributed through Qualtrics (Provo, UT).  
 
Missing Data 
Among 217 eligible respondents, missingness from the survey occurred for the following 
demographic variables: sex (n = 56), race/ethnicity, marital status, employment, 
education, and number of working adults (n = 58). At least one missing demographic 
variable occurred in 85 (39%) respondents. A missing indicator variable was created in 
order to test whether missingness affected responses to a random selection of questions 
from the domains. In all instances, missingness was not associated with the response 
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and subsequent analyses were therefore made only for individuals that had complete 
data without imputation of missing data.  
 
Statistical Analysis 
Data were summarized using frequencies, percentages, medians, and interquartile 
ranges (IQR). Associations between categorical variables were tested using a Fisher's 
exact (when n < 5) or chi-squared tests, whereas associations between ordinal variables 
used a Wilcoxon rank sum test. Questions using a 5-point Likert scale were ultimately 
dichotomized to compare the two affirmative responses (i.e., “strongly agree” and 
“somewhat agree”) with the remaining three options (i.e., “strongly disagree,” “somewhat 
disagree,” and “neutral”). Statistical significance was assessed at the  = 0.05 





A total of 217 eligible individuals completed the survey including 27 (12%) that were 
parents of children being evaluated or waitlisted for a liver transplant and 190 (88%) that 
were parents of children that had received a transplant; 34 individuals were excluded 
because their child was neither being evaluated or waitlisted for transplant, nor had they 
received a transplant. There was no difference in the demographic characteristics of 
respondents of children that were evaluated/waitlisted compared to children that had 
already been transplanted (Table 1). Respondents were mostly female (93%) with a 
median age of 38 (IQR: 34-45) years and the median age of the child was 5 (2-11) 
years. The insurance status of participants included 64% with only private insurance, 
12% with only Medicaid, and 24% with a combination of public and private payers. The 
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majority of participants were married or living with a partner (86%). Half of respondents 
were fully employed and 61% were from families that had >1 working adult. A college 
degree was obtained by 77% of participants. Among respondents, 87% identified as 
white non-Hispanic, 4% Asian, 3% African American, 3% Hispanic, and 4% mixed/other. 
The respondents were technologically fluent, with 94% owning multiple digital devices 
(i.e., smartphones, tablets, computers) and 99% using these devices for at least 1 hour 
each day. Their health status was rated as at least “good” by 91% of respondents. 
 
Knowledge of Living-Donor Evaluation 
When asked about their understanding of living donation, 97% were aware that LDLT 
was an option and 90% knew who to ask about the process, but only 72% were 
knowledgeable about the actual steps and 69% were aware that costs were covered by 
the recipient’s insurance (Table 2). Awareness that LDLT was an option was similar for 
parents of children that are currently being evaluated or waitlisted compared to 
transplant recipients (91% vs 98%; P = 0.1), but the former were less likely to know who 
to ask (65% vs 93%; P < 0.001), know the steps for evaluation (44% vs 77%; P = 0.001), 
or know that the cost of the procedure was covered by the recipient’s insurance (43% vs 
77%; P = 0.004).  
 
Insurance status (exclusively public vs private/mixed) was not associated with general 
awareness that LDLT is an option (100% vs 98%; P = 0.6), knowledge about which 
provider to ask about the evaluation (89% vs 95%; P = 0.3), or knowledge that the donor 
surgery is covered by the recipient’s insurance (61% vs 78%; P = 0.1), but respondents 
with public insurance were nearly half as likely to know the actual steps for LDLT 
evaluation (44% vs 82%; P < 0.001). Similarly, single parents were equally likely to be 
aware that LDLT is an option (96% vs 99%; P = 0.3) and which provider to ask about the 
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evaluation (92% vs 100%; P = 0.2), but significantly less likely to know the specific steps 
for the evaluation (57% vs 81%; P = 0.01) or that the cost of the donor surgery was 
covered by the recipient’s insurance (52% vs 76%; P = 0.02).  Employment status (i.e., 
full-time employment vs non-full-time employment), number of working adults in the 
house, education level, and race/ethnicity were not associated with knowledge about 
LDLT, which provider to ask about the evaluation, the steps for evaluation, or insurance 
coverage for the procedure.   
 
Outcomes Following Living Donation 
Only 38% of respondents correctly understood that outcomes following living donation 
are better than deceased donation, whereas 46% thought the outcomes were the same, 
17% thought deceased donation was worse, and 9% of respondents had no opinion 
about relative outcomes for each surgery. Understanding about outcomes following 
LDLT was not associated with whether the respondent’s child was currently being 
evaluated or waitlisted or had been transplanted (P = 0.3). Single parents were more 
likely than parents that were married or living with a partner to believe outcomes were 
worse following living donation (22% vs 4%; P = 0.03); otherwise, insurance, 
educational, employment, or race/ethnicity were not associated with knowledge about 
outcomes following LDLT compared to deceased donation. 
 
Social Network 
Over 90% of respondents indicated they had at least 2 individuals with whom they were 
comfortable asking to be a living donor. The number of people with whom respondents 
would be comfortable asking to consider living donation for their child was independent 
of a respondent’s sociodemographic background. Likewise, whereas 26% of 
respondents believed that asking a friend or family member about potentially being a 
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donor may cause stress in the relationship, this belief was independent of 
sociodemographic variables. Respondents with public insurance were less likely than 
those with private insurance to actually know someone who had been a living donor 
(44% vs 56%; P = 0.005) as were individuals without a college degree compared to 
those with a college degree (64% vs 85%; P = 0.007). Employment status, number of 
working adults in household, or race/ethnicity were not associated with knowing 
someone who had been a living donor.  
 
Trust in Medical Community 
Although some respondents were told they were ineligible to donate (16%), among 
parents that perceived they could be considered potential LDLT donors (n = 157), 97% 
were comfortable with the idea. Over 90% of respondents indicated that they liked their 
doctor, trusted their doctor to do the right thing for their child, generally agreed with the 
treatment plan, and felt their doctor answered all their questions (Table 3). Respondents 
with public insurance were equally likely to trust their child’s doctor, agree with the 
medical plan, and feel their questions were answered but were less likely to like their 
doctor than individuals with private insurance (83% vs 97%; P = 0.04). Neither parental 
education level nor marital status were associated with trust in the medical community. 
However, while having ≤1 working adult in the household was not associated with trust 
in the medical community, fully-employed parents were more likely to trust their doctor 
(99% vs 91%; P = 0.03) and feel their questions were answered (99% vs 89%; P = 





Overall, 82% of respondents believed they were generally well-informed by their 
healthcare team about LDLT (Table 4). Parents of children who are currently undergoing 
evaluation or waitlisted were less likely than children who have been transplanted to feel 
well-informed (43% vs 87%; P < 0.001). Individuals with public insurance were less likely 
to feel well-informed about LDLT (67% vs 87%; P = 0.03) whereas this perception did 
not vary by marital status, education, employment, or race/ethnicity. Only 86% of 
respondents believed they were well-informed about complications to the recipient and 
76% believed they were well-informed about potential complications to the donor, and 
this was independent of sociodemographic background.  
 
With respect to feeling well-informed about the impact of living donation on the donor’s 
work (i.e., time off), 75% felt they were adequately informed, but this was lower in 
individuals on public insurance (44% vs 81%; P = 0.001). Otherwise, education, 
employment, marital status or race were not associated with whether respondents 
considered themselves fully informed about the impact of LDLT on donor work.  
 
DISCUSSION 
There is tremendous need to better understand barriers toward access of LDLT for 
pediatric candidates given that outcomes following LDLT are better than deceased 
donation and that the procedure offers opportunities to reduce waitlist morbidity and 
mortality. Among our cohort of largely healthy parents, a number of important 
observations can be identified regarding barriers toward LDLT and factors that potentiate 
these barriers. First, while nearly all parents were broadly aware of living donation as an 
option, substantially fewer were knowledgeable about the process including which 
providers to ask, what are the steps, and that the procedure is covered by insurance. 
Parents with public insurance or from single-parent households were less likely to 
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understand the process. Second, 18% of parents felt they were generally poorly 
informed by their providers about LDLT and 24% felt they were specifically not well-
informed about risk to the donor, or the impact on the donor’s work. Third, only 
approximately one-third of parents correctly knew that outcomes following LDLT were 
actually better than deceased donation. Fourth, while many of the respondents were 
generally comfortable asking several people to be a living donor, one quarter believed 
this may cause stress in a relationship. And fifth, low use of living donation cannot be 
explained by a lack of trust in the medical community.  
 
While most respondents were aware that living donation is an option, it is concerning 
that a large percentage of parents do not know basic aspects of the process such as 
which provider to ask, what are the relative outcomes compared to deceased donation, 
and what are complications for the donor and recipient. One explanation may be that 
many respondents are receiving care for their children at centers where LDLT is not 
performed and that less information may be provided to families at these centers. 
Presently, LDLT is only offered in approximately a quarter of all programs.77 However, it 
is an ethical requirements for informed consent that people be well-informed about all 
options, and the Center for Medicare Services mandates that people undergoing 
evaluation for transplantation be presented with patient and graft survival for both 
deceased and living donation.78 Therefore, a lack of availability of LDLT at a specific 
center is not a sufficient explanation to justify a lack of understanding about its 
outcomes, the process, and the specific risks and benefits of the procedure.  
 
Several encouraging observations should be noted. First, individuals generally trusted 
their doctors and believed that their healthcare team would do the right thing for the 
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patient. Second, individuals generally reported strong social networks and willingness to 
discuss living donation with other people.  
 
The association between specific sociodemographic characteristics and reduced use of 
LDLT have been reported elsewhere.79 In a large registry study of children with biliary 
atresia, individuals with public insurance had significantly lower rates of LDLT, which is 
not surprising given that public insurance can serve as a proxy for lower income and 
fewer resources, alongside the observation that the procedure is associated with 
increased financial burden for donors.67,71 Here, we explore in greater detail other 
potential mechanisms that may act as barriers, including that this population is less likely 
to know the steps for living donor evaluation, to feel generally well-informed about LDLT, 
to understand how LDLT may impact their work and other responsibilities, and to know 
someone that had gone through the process. Lack of adequate information is also 
evident with single parents and this finding has been reported from adult studies as 
well.80   
 
Sociodemographic variables such as insurance status likely mediate the relationship 
between race/ethnicity and access to living donation, and substantial research exists in 
the adult liver and kidney literature as well as pediatric kidney literature that may help 
elucidate these barriers.81 For example, studies have identified that African Americans 
are more likely to be concerned about the procedure’s impact on personal relationships 
and concerns about finances, to have greater distrust of the medical community, and to 
have decreased medical literacy as it relates to LDLT.14,45,56,57 Among African Americans, 




Unfortunately, one major limitation of our study was the low response rate of non-
Caucasian individuals in our sample, making it impossible to understand any potential 
impact of race/ethnicity on the use of living donation in pediatric liver candidates; 
although Facebook is used by all racial/ethnic groups equally at around 75%, it has been 
reported that African Americans may be less willing to share health information online 
compared with other groups.83–85 A second limitation of our study is that it was 
distributed over social media, allowing for the possibility that our sample is not broadly 
representative of the population of parents of children with end-stage liver disease. 
Rather, our cohort may represent a sample that is both more trusting of healthcare 
providers/scientists such that they are willing to complete a survey, and that they are 
more open to sharing their health experiences and struggles. 
 
These findings highlight the need for programs to provide additional education to the 
community, through public forums, social media, and other mechanisms to provide 
comprehensive information to all individuals.86 Although we didn't measure health 
literacy directly, education level has been shown to correlate with health literacy in the 
transplant population.87,88 Navigating the transplant process, from referral through 
surgery, has been shown to depend heavily on education, and this need is especially 
true for living donor transplantation.89,90 Fortunately, evidence exists from clinical trials of 
adult kidney transplant candidates that educational programs can lead to higher 
knowledge and fewer concerns with living donation as well as an increase the number of 
donor inquiries.91 Application of education programs regarding LDLT to the pediatric liver 
community can therefore be reasonably expected to increase its use, further decrease 




Table 1: Demographic characteristics of survey respondents 
 All Evaluated/ 
Waitlisted 
Transplanted P 
Female, n (%) 149 (93) 14 (88) 135 (93) 0.3 
Parent age (years), median 
(IQR) 
38 (34-45) 36 (31-42) 38 (34-45) 0.2 
Child age (years), median 
(IQR) 
5 (2-11) 4 (1-6) 5 (2-11) 0.2 
Insurance, n (%)     
public 18 (12) 3 (20) 15 (11) 0.1 
private 93 (64) 6 (40) 87 (66)  
mixed 35 (24) 6 (40) 29 (22)  
Marital status, n (%)     
single 23 (14) 2 (13) 21 (15) 0.9 
married/partner 136 (86) 14 (88) 122 (85)  
Employment, n (%)     
full-time 81 (51) 9 (56) 72 (50) 0.4 
part-time 21 (13) 3 (19) 18 (13)  
homemaker 43 (27) 2 (13) 41 (29)  
other 14 (9) 2 (13) 12 (8)  
Number of working adults 
in house, n (%) 
    
≤1 62 (39) 5 (31) 57 (40) 0.5 
>1 97 (61) 11 (69) 86 (60)  
Education, n (%)     
less than college degree 36 (23) 5 (31) 31 (22) 0.4 
college degree 123 (77) 11 (69) 112 (78)  
Race/ethnicity, n (%)     
Caucasian non-Hispanic 138 (87) 13 (81) 125 (87) 0.4 
other 21 (13) 3 (19) 18 (13)  
Device ownership, n (%)     
multiple 149 (94) 14 (88) 135 (94) 0.3 
single (smartphone or 
computer) 
10 (6) 2 (13) 8 (6)  
Access of internet >1 hour 
per day, n (%) 
157 (99%) 16 (100) 141 (99) 0.9 
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Health status (of 
respondent), n (%) 
    
poor or fair 15 (9) 0 (0) 15 (11) 0.4 
good, very good or 
excellent 



















 % P % P % P % P 
Overall 97 -- 90 -- 72 -- 69 -- 
Transplant status         
  evaluated/waitlisted 91 0.1 65 <0.001 43 0.001 43 0.004 
  transplanted 98  93  77  73  
Insurance           
  public 100 0.6 89 0.3 44 <0.001 61 0.1 
  mixed or private 98  95  82  78  
Marital status         
  single 96 0.3 100 0.2 57 0.01 52 0.02 
  married/partner 99  92  81  76  
Employment           
  full-time 99 0.9 96  0.1  77 0.8 73 0.9 
  other 99  90   78  73  
Number of working 
adults in house 
        
  ≤1 98 0.9 95 0.5 77 0.9 71 0.7 
  >1 99  92  77  74  
Education          
  less than college 
degree 
100 0.9 92 0.7 78 0.9 67 0.3 
  college degree 98  94  77  75  
Race/ethnicity         
  Caucasian non-
Hispanic 
99 0.9 94 0.2 77 0.7 75 0.2 

















 % P % P % P % P 
Overall 94  -- 93  -- 93  -- 94  -- 
Insurance           
  public 94  0.9  89  0.3  83  0.04   94  0.5 
  mixed or private 95   95   97   96   
Marital status         
  single  100 0.6  100  0.4 100 0.4  100  0.4  
  married/partner 94   92  93   94   
Employment           
  full-time 99  0.03  96   0.1 95   0.5  99 0.02  
  other 91   90   92   89   
Number of working 
adults in house 
        
  ≤1 92  0.3  89   0.1 92  0.5  91  0.1  
  >1 97   96   95   97   
Education          
  less than college 
degree 
89  0.1  89   0.3 92   0.7 94  0.9  
  college degree 97   94   94   94   
Race/ethnicity         
  Caucasian non-
Hispanic 
95  0.9  93   0.6 93  0.9  95   0.3 













 % P % P % P % P 
Overall 82 -- 86 -- 76 -- 75 -- 
Transplant status         
  evaluated/ 
waitlisted 
43 <0.001 75 0.3 75 0.9 69 0.5 
  transplanted 87  87  76  76  
Insurance           
  public 67 0.03 72 0.05 61 0.1 44 0.001 
  mixed or private 87  89  79  81  
Marital status         
  single 74 0.1 91 0.7 70 0.4 74 0.9 
  married/partner 86  84  77  75  
Employment           
  full-time 85 0.7 89 0.2 79 0.4 78 0.4 
  other 83  82  72  71  
Number of working 
adults in house 
        
  ≤1 85 0.7 87 0.7 77 0.8 75 0.9 
  >1 84  85  75  74  
Education          
  less than college 
degree 
81 0.5 89 0.8 74 0.8 66 0.2 
  college degree 85  84  76  77  
Race/ethnicity         
  Caucasian non-
Hispanic 
85 0.7 86 0.5 76 0.9 74 0.6 
  other 81  81  76  81  
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Background: The increased use of split liver transplantation (SLT) represents one 
strategy to increase the supply of organs. Although outcomes after SLT and whole liver 
transplantation (WLT) are similar on average among pediatric recipients, we 
hypothesized that the relationship between graft type and outcomes may vary depending 
on patient, donor, and surgical characteristics.  
 
Methods: We evaluated graft survival among pediatric (<18 years), deceased-donor, 
liver-only transplant recipients from March, 2002, until December, 2015, using data from 
the Scientific Registry of Transplant Recipients. Graft survival was assessed in a Cox 
proportional hazards model, with and without effect modification between graft type and 
donor, recipient, and surgical characteristics, to identify conditions where the risk of graft 
loss for SLT and WLT were similar.  
 
Results: In a traditional multivariable model, characteristics associated with graft loss 
included donor age >50 years, recipient weight <10 kg, acute hepatic necrosis, 
autoimmune diseases, tumor, public insurance, and cold ischemia time (CIT) >8 hours. 
In an analysis that explored whether these characteristics modified the relationship 
between graft type and graft loss, many characteristics associated with loss actually had 
similar outcomes irrespective of graft type including weight <10 kg, acute hepatic 
necrosis, autoimmune diseases, and tumor. In contrast, several subgroups had worse 
outcomes when SLT was used, including recipient weight 10−35 kg, non-BA cholestasis, 
and metabolic disease. Allocation score, share type, or CIT did not modify risk of graft 
type and graft failure.  
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Conclusion: Although one might anticipate that individuals with higher rates of graft loss 
would be worse candidates for SLT, data suggest that these patients actually have 
similar rates of graft loss. These findings can guide surgical decision-making and may 





Pediatric liver transplantation provides life-saving therapy for children with end-stage 
liver disease and other metabolic conditions but continues to be hindered by a scarcity of 
available organs.5 Waitlisted children typically receive fewer offers for deceased donor 
organs than adults, suggesting that they are especially vulnerable to an imbalance in 
need and availability.25 Consequently, neonates have the highest rate of waitlist mortality 
for any age group, with nearly one-third of waitlisted neonates dying before receiving a 
suitable offer.7  
 
The use of split liver transplantation (SLT) represents one opportunity to increase the 
supply of organs and has the potential to shorten waitlist times and decrease pre-
transplant morbidity and mortality, particularly for children. Recent evidence suggests 
that outcomes following SLT are now likely comparable to whole liver transplantation 
(WLT) for both pediatric and adult recipients.19,59,92 At the same time, the benefit of SLT 
may vary among patients with different donor, recipient, or surgical characteristics. For 
example, a study of adult transplant recipients concluded that graft failure following SLT 
and WLT was equivalent on average, but that status 1 recipients had poorer outcomes 
when receiving SLT compared to WLT.19 Analysis of recipient, donor, and surgical 
characteristics can serve to identify optimal individuals for higher-risk organs that are not 
at increased risk of graft loss as well as suboptimal recipients for whom whole livers 
would yield better outcomes.93  
 
In pediatric liver transplantation, several donor, recipient, and surgical characteristics 
have been shown to influence outcomes, such as donor age, cause of death, fulminant 
disease in the recipient, and prolonged cold ischemia time (CIT).27,32 As with adults, 
these characteristics may yield subgroups of pediatric candidates whose outcomes are 
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worse when receiving SLT, and other groups for whom outcomes are not affected by 
graft type. Better understanding of which characteristics are modified by graft type would 
serve to better inform surgical decision-making about which recipients are appropriate 
for SLT and could potentially inform policy to promote SLT. In this study, we used a large 
national registry to explore which characteristics modify the association between graft 
type and graft failure among pediatric deceased organ recipients in order to better 




This study used data from the Scientific Registry of Transplant Recipients (SRTR). The 
SRTR data system includes data on all donors, wait-listed candidates, and transplant 
recipients in the U.S., submitted by the members of the Organ Procurement and 
Transplantation Network (OPTN), and has been described elsewhere.22 The Health 
Resources and Services Administration (HRSA), U.S. Department of Health and Human 
Services, provides oversight to the activities of the OPTN and SRTR contractors. 
 
Study Population 
We identified 5,345 pediatric liver-only, first-time transplant recipients of a deceased 
WLT or SLT who received an organ between March 1, 2002 (i.e., after implementation of 
the PELD/MELD system), and December 31, 2015; patients with missing weight (n = 1) 
or missing CIT (n = 284) were excluded. We compared donor, recipient, and surgical 




All individuals were defined as having an SLT if they received a portion of a deceased 
donor graft. Sensitivity analyses exploring the impact of organs used by one recipient 
(i.e., “cut down”) versus two recipients, and in vivo versus ex vivo splits showed no 
difference in graft failure, a finding consistent with other studies demonstrating similar 
occurrence of graft failure, biliary strictures, and vascular thromboses.12,19  
 
Graft Survival  
Graft failure was identified as any reported graft failure or death (i.e., “all cause graft 
loss”). This means that: (1) all deaths are attributed to a graft failure, but not all graft 
failure leads to death; and (2) risk of graft failure is always greater than risk of death. The 
functional form for recipient, donor, and surgical characteristics were explored using 
Kaplan-Meier curves and log-rank tests. We used Cox proportional hazards models to 
characterize the association between allograft type and graft survival after adjustment for 
the following variables: donor age and race, cause of death, recipient weight at 
transplant, recipient sex, recipient race/ethnicity, underlying disease, laboratory 
PELD/MELD at transplant, status 1 designation, insurance type, CIT, and share type 
(i.e., local, regional or national). The decision to include these specific variables in the 
final model for multivariable regression was derived from associations between 
covariates with risk factors and the outcome in both the published literature as well as 
statistical tests within this cohort. Recipients were censored upon re-transplantation or 
multi-organ transplantation (e.g., liver-kidney).  
 
Effect Modification  
To identify specific recipient, donor, and surgical characteristics that modify the effect of 
allograft type on graft survival, we performed Cox regression analysis with effect 
modification between allograft type with additional covariates for which an a priori 
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hypothesis existed that the association between the covariate and graft failure may vary 
by allograft type. Test for effect modification was assessed in an unadjusted analysis as 
well as a parsimonious model that adjusted for donor cause of death, recipient weight, 
recipient diagnosis, allocation score, share type, and CIT as previously described.93 
Donor age was excluded from effect modification analysis given the small number of 
individuals receiving a split from a donor >50 years (n < 100). Donor race, recipient race, 
and recipient insurance were excluded due to there being no a priori reason to consider 
that the association between allograft type and graft failure would vary by these 
characteristics. From this model, the relative impact of SLT versus WLT could be 
evaluated, with factors that exacerbated the impact of SLT versus WLT being defined as 
“optimal,” whereas those that had no impact (or attenuated the impact) on SLT versus 
WLT were defined as “suboptimal.”  
 
Potential for Increased SLT 
In order to further quantify opportunities to increase the use of SLT among pediatric liver 
transplant candidates, we identified the number of waitlisted individuals who died, or 
were delisted due to medical unsuitability or declining health, having been on the waitlist 
for at least 7 days in the period from March 1, 2002 to December 31, 2016 (n = 1,160); 
since it can be reasonably assumed that individuals would only be listed if they were 
appropriate candidates for transplant, individuals delisted 7 days later due to death or 
medical unsuitability represent instances where an offer through SLT would have 
benefited the candidates. The number of individuals with optimal characteristics that had 
been listed but then delisted served to provide an estimate of the potential reduction in 




All statistical tests used a two-sided  of 0.05. Confidence intervals are reported using 
the method of Louis and Zeger, as previously reported.24 All analyses were performed 
using STATA 14.0 (College Station, TX, USA). This study was approved by the 
Institutional Review Board of Johns Hopkins University School of Medicine. No organs 




Among 5,345 pediatric recipients in our study, 1,694 (31.7%) received an SLT and 3,651 
(68.3%) received a WLT (Table 1). SLT recipients were less likely than WLT recipients 
to have a donor that was <18 years (59.4% for SLT and 84.3% for WLT) and more likely 
to have a donor between 18 and 50 years (38.7% vs 13.6%; P < 0.001). SLT recipients 
were less likely to have a donor with anoxia (19.5% vs 35.1%) and more likely that the 
donor had head trauma (63.1% vs 49.8%; P < 0.001). A larger percentage of SLT 
recipients were <10 kg (51.7% vs 32.9%; P < 0.001), had biliary atresia (BA) (44.2% vs 
36.0%; P < 0.001), and were status 1 (37.7% vs 31.2%; P < 0.001). SLT recipients were 
less likely to receive the organ from a national share (4.7% vs 23.5%; P < 0.001), but 
CIT did not vary between the two graft types.  
 
Graft Failure  
Although SLT was associated with increased graft failure in an unadjusted model (HR: 
1.031.171.32), there was no evidence of increased risk after adjustment for confounding 
donor, recipient, and surgical characteristics, on average among the entire study 
population (aHR: 0.911.071.24; Table 2). Characteristics associated with graft failure in a 
traditional multivariable model included donor age 18−50 years (aHR: 1.051.251.48) and 
≥50 years (aHR: 1.922.663.68), recipient weight <10 kg (aHR: 1.241.441.69), recipients with 
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acute hepatic necrosis (aHR: 1.231.571.99), autoimmune diseases (aHR: 1.552.052.71), tumor 
(aHR: 1.571.972.47), and other diseases (aHR: 1.191.451.76), but status 1 was not associated 
with greater graft failure (aHR:  0.750.891.06 ). CIT was also associated with graft failure at 
8−12 hours (aHR: 1.061.221.39) and ≥12 hours (aHR: 1.201.451.74). Increased graft failure 
was also seen in unadjusted model for stroke (HR: 1.221.481.80), recipient weight ≥35 kg 
(HR: 1.181.391.62), and an allocation score ≥30 or status 1 (HR 1.211.381.58), but these were 
not independently significant after adjusting for other confounders.  
 
Effect Modification 
To determine if specific characteristics modified the effect between graft type and graft 
failure, several variables were tested in unadjusted and adjusted models. In these 
models, a coefficient of 1 (or a non-significant coefficient at the 95% confidence level) 
indicates that, for individuals within that subcohort, the risk of graft failure did not vary 
between individuals receiving an SLT or WLT (Figure). Alternatively, a coefficient of 1.4 
means that, among individuals with that specific characteristic (e.g., a specific weight 
category), individuals who received a SLT had 1.4 times the risk of graft failure than 
individuals with a WLT. In general, subcohorts with the highest overall graft failure were 
not further negatively impacted by having an SLT vs WLT, and therefore would be 
optimal candidates for SLT, whereas recipients with overall favorable outcomes had 
higher rates of graft failure with SLT compared to WLT, and would be suboptimal 
candidates. For example, recipient weight <10 kg was associated with increased graft 
failure in general (Table 2, aHR: 1.241.441.69), but this risk was the same irrespective of 
graft type (Figure, aHR: 0.821.001.22) suggesting this is an optimal characteristic for SLT. 
In contrast, recipients with weight between 10 and 35 kg had overall lower risk of graft 
failure but actually had 1.46 times higher rate of graft failure following SLT compared to 
WLT (aHR: 1.101.371.70). A similar pattern was evident when considering indication for 
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transplant, where an equivalent risk of graft failure in SLT and WLT existed for recipients 
that had the highest overall risk─acute hepatic necrosis (aHR for SLT vs WLT: 
0.801.111.53), autoimmune disease (aHR SLT vs WLT: 0.921.713.17), and tumor (aHR SLT 
vs WLT: 0.721.031.48)─whereas SLT was associated with higher graft failure, and 
suboptimal, for individuals that generally had favorable overall risk such as non-BA 
congenital cholestasis (aHR for SLT vs WLT: 1.132.144.07) and metabolic disorders (aHR 
SLT vs WLT: 1.081.572.28). Notably, BA had generally low risk of graft failure, and was not 
adversely impacted by use of SLT (aHR SLT vs WLT: 0.881.091.36). Graft type did not 
modify the association between allocation score and graft failure, with similar risk for 
SLT versus WLT in individuals with PELD/MELD <30 (aHR: 0.951.181.47), ≥30 without 
status 1 (aHR: 0.981.301.72), and ≥30 with status 1 (aHR: 0.941.151.41). 
 
Although higher risk of graft failure was seen with CIT >8 hours, this association was not 
modified by graft type in recipients with CIT 8-12 hrs (aHR SLT vs WLT: 0.851.071.34) or 
CIT ≥12 hrs (aHR SLT vs WLT: 0.971.361.92). Among individuals with CIT <8 hours, there 
was a trend toward increased graft failure in individuals when receiving SLT compared to 
WLT (aHR SLT vs WLT: 1.001.201.43). Graft type did not modify risk of graft failure in 
individuals who received a local share (aHR SLT vs WLT: 0.961.181.46) or regional/national 
share (aHR SLT vs WLT: 0.981.161.38). While donor stroke was not generally associated 
with graft failure, recipients of SLT from donors with stroke had increased graft failure 
compared to WLT from donor with stroke (aHR SLT vs WLT: 1.051.462.02).  
 
Potential for Increased SLT 
For those characteristics in which some subcohorts were optimal (i.e., weight <10 kg; all 
recipient diagnoses except non-BA cholestasis and metabolic disorder), we identified the 
number of recipients that were waitlisted for at least 7 days but ultimately died or were 
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delisted due to medical unsuitability while waiting for an offer over the study period (i.e., 
178 months; n = 1,160). Among waitlist deaths, 451 pediatric candidates were <10 kg 
and 348 (78%) were on the waitlist for at least 7 days before death or delisting due to 
poor health indicating that as many as approximately 23 candidates per year may likely 
have benefitted from increased availability of SLT. Furthermore, within this group of 348 
pediatric candidates, 320 (92%) had optimal underlying conditions and 28 had 
suboptimal conditions (i.e., 13 with non-BA neonatal cholestasis and 15 with metabolic 
disorders) indicating that as many as 22 children per year with optimal weight and 
underlying disease died after waiting at least 7 days for an organ and would likely have 
benefited from increased use of SLT.  
 
DISCUSSION 
Increasing evidence suggests that outcomes following SLT and WLT are similar.19,21,59,92 
However, this assessment should not be taken to indicate that risk of graft failure is 
equivalent for all subgroups of patients. While there may be a tendency by healthcare 
providers to anticipate that the sickest children with the highest rates of pre-transplant 
mortality (e.g., PELD/MELD ≥30, or status 1) would be relatively poorer candidates for 
SLT and have worse outcomes, our findings from this national study of 5,345 pediatric 
recipients indicate that the opposite is true. Specifically, characteristics associated with 
overall higher rates of graft failure (e.g., recipient weight <10 kg; recipient diagnosis of 
acute hepatic necrosis, autoimmune disorders, or tumor; and CIT ≥ 8 hours) had 
equivalent risk of graft failure among SLT recipients when compared to WLT. At the 
same time, pediatric recipients with the lowest overall risk of graft failure (e.g., recipient 
weight 10-35 kg; non-BA congenital cholestasis, metabolic disorders; CIT <8 hours) 
fared worse when they received a SLT compared to WLT. These findings were 
independent of pre-transplant mortality risk as determined by PELD/MELD.  
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Our findings that graft failure among children less than 10 kg and those with status 1 are 
not adversely impacted by the type of deceased donor allograft type dovetails with the 
fact that patients with these characteristics are also recipients with highest rates of death 
while awaiting liver transplantation.5,94 Consequently, our findings strengthen the 
argument that there should be broader use of SLT for these fragile subgroups of children 
and that such a practice, and policy, would likely translate to important reductions in 
waitlist death, the stated goal of our current allocation system.95 Notably, broader 
geographic sharing, including national sharing, was not associated with worse outcomes 
for children. Our analysis also attempted to quantify the degree to which increased use 
of SLT could potentially reduce waitlist mortality and determined that most children that 
die on the waitlist were waiting for at least a week, and approximately half these children 
meet criteria for being an optimal recipient for SLT, with a predicted graft survival that 
would be similar for SLT and WLT. These findings should be considered in the context of 
work by Hsu et al. that showed nearly half of the children who died on the waitlist never 
received a single offer of a liver.25 Furthermore, recent research by Perito et al. showed 
that approximately half of the most “split-able” livers, by strict criteria, were not utilized 
for SLT.96  
 
While our findings show the potential for a modest, but meaningful, opportunity to reduce 
waitlist mortality following greater use of SLT for children in select groups (e.g., recipient 
weight <10 kg), there are likely several other downstream benefits as well. First, broader 
use of SLT would likely mean that many children could be transplanted at lower 
allocation scores, corresponding both to lower pre-transplant morbidity and cost. 
Second, broader use of SLT for select groups of children would then allow for greater 
number of whole organs to be available for other groups such as slightly larger children. 
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At the same time, one limitation of our study is that we did not formally incorporate an 
analysis that combined pre-transplant and post-transplant mortality (i.e., survival 
benefit). However, given that we analyzed all cause graft loss and there was no increase 
in graft failure for select recipients, it can be inferred that there is no increase in post-
transplant mortality as well. 
 
One important limitation of our study is that, through SRTR, we do not have information 
about other meaningful outcomes such as biliary strictures and vascular thromboses. 
Similarly, we do not have specific information as to why some subgroups had higher 
rates of graft failure. The SPLIT (Studies in Pediatric Liver Transplantation) Consortium 
published outcomes from 1995-2006 and identified both higher rates of graft failure as 
well as biliary strictures and vascular complications in children receiving technical-variant 
grafts.12 However, it is not clear if these complications currently exist at higher rates in 
SLT, especially given more recent reports that graft failure in SLT, both immediate and 
long-term, is currently equivalent to WLT.59 Reports from adult literature have been 
conflicting with some studies showing similar rates of biliary stricture and vascular 
thromboses, whereas other studies still showing higher rates of these surgical 
complications. Nonetheless, one likely explanation for higher rates of graft failure among 
certain groups is that they have higher rates of these well-established complications 
leading to graft failure.  
 
A second limitation of our study is that it is derived from observational, as opposed to 
experimental, data; randomized trials would be impractical so observational studies 
represent the best opportunity to identify the benefit of different types of allografts. In this 
instance, it is possible that favorable outcomes seen in SLT are due to careful candidate 
selection on the part of healthcare teams. However, this potential for bias is not likely to 
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impact our analysis since we have adjusted for many known characteristics associated 
with disease severity including both PELD/MELD, and therefore are making 
comparisons among people with similar health status. Nonetheless, residual 
confounding of disease severity may occur. A final limitation is that the sample size was 
very small for certain subcohorts (e.g., weight >35 kg) making it hard to obtain a precise 
estimate for the relative impact of SLT versus WLT in these groups.  
 
Although many considerations go into the decision to use SLT for a specific patient, 
there is clear agreement in the transplant community that demand for organs exceed the 
supply, and that minimization of pre-transplant mortality risk should be the highest 
priority. In the context of demonstrably equivalent outcomes for adult recipients of SLT, 
our findings further support that greater use of SLT in the majority of recipients can 
address the problem of organ scarcity such that fewer children would die while awaiting 




Table 1: Characteristics of 5,345 pediatric deceased donor liver transplants 
performed in the United States in the PELD/MELD era by graft type 
Characteristic WLT SLT P  
Total (N, %) 3,651 (68.3) 1,694 (31.7)   
Donor      
Age (years)    
 <18 3,079 (84.3)  1,008 (59.5)  <0.001 
 18-50 497 (13.6)  656 (38.7)   
 ≥50  75 (2.1) 30 (1.8)   
Female 1,553 (42.5)  644 (38.0) 0.002 
Ethnicity/race       
 Caucasian, non-Hispanic 2,015 (55.2)   1,050 (62.0) <0.001 
 African American 765 (21.0)  260 (15.4)   
 Hispanic 736 (20.2)  331 (19.5)   
 Asian 72 (2.0)  25 (1.5)   
 Mixed/other 63 (1.7)  28 (1.7)   
Cause of death    
  Anoxia 1,281 (35.1)  331 (19.5)   <0.001 
  Stroke  382 (10.5)  225 (13.3)  
  Head trauma  1,816 (49.8)  1,069 (63.1)  
 unknown/other  172 (4.7)  69 (4.1)  
Recipient 
Weight (kg)    
 <10 1,201 (32.9) 875 (51.7) <0.001 
 10-35  1,367 (37.4)  710 (41.9)   
 ≥35 1,083 (29.7)  109 (6.4)   
Female 1,887 (51.7)  847 (50.0)   
Ethnicity/race    
 Caucasian, non-Hispanic 1,919 (52.6)  820 (48.4)   <0.001 
 African American  639 (17.5)  270 (15.9)  
 Hispanic  772 (21.2)  450 (26.6)  
 Asian  199 (5.5)  102 (6.0)  
 Mixed/other  122 (3.3)  52 (3.1)  
Diagnosis    
 Biliary atresia (BA) 1,315 (36.0)  748 (44.2)  <0.001  




 Autoimmune  229 (6.3)  28 (1.7)  
 Congenital cholestasis (non-BA)  148 (4.1)  91 (5.4)  
 Metabolic  561 (15.4)  219 (12.9)  
 Tumor  346 (9.5)  170 (10.0)  
 Other  581 (15.9) 216 (12.8)   
Allocation score at transplant    
 aPELD/MELD <30, non-status 1 1,657 (45.4)  618 (36.5)  <0.001 
 aPELD/MELD ≥30, non-status 1 854 (23.4)  438 (25.9)  
 aPELD/MELD ≥30, status 1 1,140 (31.2)  638 (37.7)  
Insurance    
 Private 1,731 (47.4) 715 (42.2) <0.001 
 Public 1,791 (49.1) 935 (55.2)  
 Other/missing 129 (3.5) 44 (2.6)  
Surgery 
Share type    
 Local 1,285 (35.2)  744 (43.9)  <0.001  
 Regional 1,509 (41.3)  871 (51.4)   
 National 856 (23.5)  79 (4.7)   
Cold ischemia time (hours)    
 <8 2,190 (60.0)  1,009 (59.6)  0.09 
 8-12 1,054 (28.9)  525 (31.0)   
 ≥12 406 (11.1)  160 (9.5)   
WLT = whole liver transplant; SLT = split liver transplant 
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Table 2: Characteristics associated with graft failure in pediatric recipients  
Characteristic Unadjusted Multivariable 
  HR P aHR P 
Split liver transplant 1.031.171.33 0.02 0.911.071.24 0.4 
Donor 
Age (years)     
 <18    -- -- -- -- 
 18-50 1.221.401.61 <0.001  1.051.241.48  0.01 
 ≥50 2.453.234.26 <0.001  1.912.643.65  <0.001 
Race/ethnicity     
 Caucasian -- -- -- -- 
 African American 0.931.091.28 0.3 0.991.161.36 0.1 
 Hispanic 0.800.941.10 0.4 0.830.971.14 0.7 
 Asian 0.721.121.73 0.6 0.620.971.50 0.9 
 Mixed/other 0.580.941.52 0.8 0.610.991.61 1.0 
Cause of death     
 Anoxia -- -- -- -- 
 Stroke 1.221.481.80 <0.001 0.891.101.37 0.4 
 Head Trauma 0.961.111.28 0.2 0.901.041.21 0.6 
 Other/unknown 0.720.991.36 0.9 0.680.941.29 0.7 
Recipient 
Weight (kg)     
 <10 1.071.241.42 0.003  1.241.441.69  <0.001 
 10-35 -- -- -- -- 
 ≥35 1.181.391.62 <0.001  0.901.091.32 0.4  
Female 0.931.051.18 0.5 0.951.071.21 0.3 
Race/ethnicity       
 Caucasian -- -- -- -- 
 African American 1.051.231.44 0.01 0.951.111.32 0.2 
 Hispanic 0.901.051.22 0.5 0.800.951.11 0.5 
 Asian 0.550.751.02 0.1 0.580.791.07 0.1 
 Mixed/other 0.761.071.51 0.7 0.680.961.37 0.8 
Diagnosis     
 Biliary atresia  -- -- -- -- 
 Acute hepatic necrosis 1.351.621.94 <0.001 1.241.582.02 <0.001  
 Autoimmune 1.411.812.31 <0.001 1.552.062.72 <0.001 
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 Congenital cholestasis* 0.710.991.39 0.9 0.771.071.51  0.7 
 Metabolic 0.790.981.20 0.8 0.911.141.44  0.3 
 Tumor 1.451.772.16 <0.001 1.581.992.50 <0.001  
 Other 1.151.381.65 <0.001 1.191.461.78 <0.001 
Allocation PELD/MELD     
  <30 -- -- -- -- 
 ≥30, non-status 1 0.810.951.12 0.6 0.750.891.06 0.2 
 ≥30 and status 1 1.201.381.58 <0.001 0.891.071.28 0.5 
Insurance status     
 Private -- -- -- -- 
 Public 1.041.171.33 0.01 1.061.211.38 0.006 
 Other/missing 0.440.681.04 0.1 0.480.741.15 0.2 
Surgery 
Share     
  Local -- -- -- -- 
  Regional 0.830.941.07 0.4 0.830.951.09 0.4 
  National 0.710.851.01 0.1 0.700.861.06 0.1 
Cold ischemia time (hours)     
  <8  -- -- -- -- 
  8-12 1.031.181.35 0.02 1.061.211.39 0.005 
  ≥12 1.151.381.65 <0.001 1.201.451.74 <0.001 
*non-biliary atresia congenital cholestasis (e.g., Alagille syndrome)  
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Table 3: Analysis of effect measure modification of graft type on donor, recipient 
and surgical characteristics with graft failure  
Characteristic Unadjusted SLT vs WLT* Adjusted SLT vs WLT 
  HR P aHR P 
Donor cause of death         
 non-Stroke 0.971.121.25  0.1 0.981.131.31  0.1 
 Stroke 1.031.401.92 0.03 1.051.462.02 0.02 
Recipient weight (kg)     
 <10 0.851.031.25  0.8 0.821.001.22   0.8  
 10-35 1.231.521.88  <0.001 1.101.371.70   0.004 
 ≥35  0.931.341.94 0.1 0.921.341.90  0.1 
Diagnosis     
 Biliary atresia (BA) 0.921.151.43   0.2 0.861.081.34   0.5  
 Acute hepatic necrosis  0.781.071.45 0.7  0.781.091.50 0.6 
 Autoimmune disease 0.891.653.05 0.1 0.921.703.15 0.1 
 Congenital cholestasis  1.182.244.25 0.01 1.102.093.97 0.02 
 Metabolic 1.101.602.32 0.01 1.061.572.28 0.02 
 Tumor 0.711.021.46 0.9 0.701.011.45 1.0 
 Other  0.881.201.65 0.3  0.811.121.56  0.5 
Allocation PELD/MELD     
  <30  0.881.081.34 0.5  0.941.171.46  0.2 
 ≥30, non-status 1  0.961.261.66 0.1  0.961.271.69  0.1 
 ≥30 and status 1  0.941.141.38 0.2  0.921.131.38  0.3 
Share     
  Local  0.961.161.41 0.1  0.961.181.46 0.1 
 Regional/national  0.981.161.37 0.1  0.981.161.38 0.1 
Cold ischemia time (hours)     
  <8   0.981.171.39 0.1  1.001.201.43 0.05  
  8-12  0.881.101.37 0.4  0.851.071.34  0.6 
  ≥12  1.001.411.97 0.05  0.971.361.92  0.1 
SLT = Split liver transplant; WLT = Whole liver transplant 
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Chapter 6. Conclusion  
 
Our research demonstrates that outcomes for pediatric liver transplant recipients 
following technical-variant donation, including both living-donor liver transplantation 
(LDLT) and split liver transplantation (SLT), are now at least equivalent to whole liver 
transplantation (WLT). Given that LDLT and SLT are each used in only approximately 
10-15% of children who receive a transplant, our findings suggest tremendous 
opportunity for greater use of these newer surgeries as well as the potential to mitigate 
the consequences of organ scarcity: increased waitlist morbidity and mortality.  
 
Our research on national trends in outcomes for pediatric liver transplant recipients 
identified that the early experience (i.e., 2002-2009) of SLT, a more complex surgery, 
showed inferior patient and graft survival. Complications in this period could be traced 
largely to inferior outcomes in the immediate post-operative period. As transplant 
programs gained more experience, risk of graft failure or death in the immediate post-
operative abated such that outcomes following SLT and WLT have more recently been 
comparable. Outcomes following LDLT were initially similar to WLT but again, with more 
experience, are now superior to WLT.  
 
Even though our findings suggest that risk of graft failure is now similar for SLT and 
WLT, some subgroups of children may be better candidates for SLT than others. Our 
analysis of donor, recipient and surgical characteristics identified that the relationship 
between graft type and graft failure was modified by the underlying disease, with higher 
graft failure only in SLT recipients that had non-BA congenital cholestasis and metabolic 
disorders as their underlying disorder compared to other disorders such as biliary atresia 
and acute liver failure. Similarly, recipient weight modified the relationship between graft 
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type and graft failure, with higher risk of graft failure only in those SLT recipients that 
were between 10-35 kg. These subgroups of disease and weight category were actually 
the individuals that had the lowest rates of graft failure overall but were negatively 
impacted by getting a split liver. At the same time, individuals that had higher rates of 
graft failure overall (e.g., acute liver failure, recipient weight <10 kg) had similar 
outcomes irrespective of which graft type they received.  
 
LDLT provides an opportunity to be transplanted before individuals becomes extremely 
sick and assures they will not die while waiting for an offer. But despite these benefits, 
living donation is infrequently used for pediatric liver candidates. Using the Scientific 
Registry of Transplant Recipients, we identified African-American race and use of public 
insurance as sociodemographic characteristics associated with reduced likelihood of 
LDLT and sought to further understand barriers in these groups through our survey. 
 
Our survey to parents of children awaiting a liver transplant or recipients of a liver 
transplant identifies specific barriers towards living donation. Parental understanding 
about the evaluation process was largely insufficient, with only 72% of respondents 
knowing the steps and 69% knowing that the cost was covered by the recipient’s 
insurance. One quarter of respondents were not informed about potential complications 
to the donor or how the surgery might impact the donor’s need for time off from work. In 
general, individuals with fewer resources such as those individuals with public insurance 
or from single-family homes were less likely to feel well-informed about the process.  
 
This an exciting for liver transplantation. The last major change in allocation occurred in 
2002 with the implementation of PELD/MELD but there is increasing understanding 
about disparities that exist in the system, and how it fails to adhere to federally-
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mandated guidance about fairness in the distribution of a scarce resource for adults and 
pediatric candidates.97 At the same time, these newer technical-variant surgeries are 
increasingly understood to provide an appropriate solution to organ scarcity. We believe 
this research provides valuable insight into how these surgeries ought to be promoted in 
the next wave of discussions about living-donor awareness and organ allocation in the 







1.  Mohammad S, Alonso EM. Approach to optimizing growth, rehabilitation, and 
neurodevelopmental outcomes in children after solid-organ transplantation. Pediatr 
Clin North Am. 2010;57(2):539-557, table of contents. 
doi:10.1016/j.pcl.2010.01.014 
2.  Alonso EM, Martz K, Wang D, et al. Factors predicting health-related quality of life 
in pediatric liver transplant recipients in the functional outcomes group. Pediatr 
Transplant. 2013;17(7):605-611. doi:10.1111/petr.12126 
3.  Limbers CA, Neighbors K, Martz K, et al. Health-related quality of life in pediatric 
liver transplant recipients compared with other chronic disease groups. Pediatr 
Transplant. 2011;15(3):245-253. doi:10.1111/j.1399-3046.2010.01453.x 
4.  OPTN: Organ Procurement and Transplantation Network. 
http://optn.transplant.hrsa.gov/latestData/step2.asp. Accessed April 21, 2014. 
5.  Kim WR, Lake JR, Smith JM, et al. OPTN/SRTR 2015 Annual Data Report: Liver. 
Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. 2017;17 Suppl 
1:174-251. doi:10.1111/ajt.14126 
6.  Buchanan P, Dzebisashvili N, Lentine KL, Axelrod DA, Schnitzler MA, Salvalaggio 
PR. Liver transplantation cost in the model for end-stage liver disease era: looking 
beyond the transplant admission. Liver Transplant Off Publ Am Assoc Study Liver 
Dis Int Liver Transplant Soc. 2009;15(10):1270-1277. doi:10.1002/lt.21802 
7.  Hsu EK, Mazariegos GV. Global lessons in graft type and pediatric liver allocation: 
A path toward improving outcomes and eliminating wait-list mortality. Liver 
Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc. 
2017;23(1):86-95. doi:10.1002/lt.24646 
8.  Freeman RB, Wiesner RH, Harper A, et al. The new liver allocation system: moving 
toward evidence-based transplantation policy. Liver Transplant Off Publ Am Assoc 
Study Liver Dis Int Liver Transplant Soc. 2002;8(9):851-858. 
doi:10.1053/jlts.2002.35927 
9.  Raia S, Nery JR, Mies S. Liver transplantation from live donors. Lancet Lond Engl. 
1989;2(8661):497. 
10.  Austin MT, Feurer ID, Chari RS, Gorden DL, Wright JK, Pinson CW. Survival after 
pediatric liver transplantation: why does living donation offer an advantage? Arch 
Surg Chic Ill 1960. 2005;140(5):465-470; discussion 470-471. 
doi:10.1001/archsurg.140.5.465 
11.  Lobritto S, Kato T, Emond J. Living-donor liver transplantation: current perspective. 
Semin Liver Dis. 2012;32(4):333-340. doi:10.1055/s-0032-1329900 
 92 
12.  Diamond IR, Fecteau A, Millis JM, et al. Impact of graft type on outcome in pediatric 
liver transplantation: a report From Studies of Pediatric Liver Transplantation 
(SPLIT). Ann Surg. 2007;246(2):301-310. doi:10.1097/SLA.0b013e3180caa415 
13.  Mathur AK, Sonnenday CJ, Merion RM. Race and ethnicity in access to and 
outcomes of liver transplantation: a critical literature review. Am J Transplant Off J 
Am Soc Transplant Am Soc Transpl Surg. 2009;9(12):2662-2668. 
doi:10.1111/j.1600-6143.2009.02857.x 
14.  Purnell TS, Hall YN, Boulware LE. Understanding and overcoming barriers to living 
kidney donation among racial and ethnic minorities in the United States. Adv 
Chronic Kidney Dis. 2012;19(4):244-251. doi:10.1053/j.ackd.2012.01.008 
15.  Segev DL, Powe NR, Troll MU, Wang N-Y, Montgomery RA, Boulware LE. 
Willingness of the United States general public to participate in kidney paired 
donation. Clin Transplant. 2012;26(5):714-721. doi:10.1111/j.1399-
0012.2012.01596.x 
16.  Sieverdes JC, Nemeth LS, Magwood GS, et al. African American kidney transplant 
patients’ perspectives on challenges in the living donation process. Prog Transplant 
Aliso Viejo Calif. 2015;25(2):164-175. doi:10.7182/pit2015852 
17.  Kim WR, Lake JR, Smith JM, et al. OPTN/SRTR 2013 Annual Data Report: liver. 
Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. 2015;15 Suppl 
2:1-28. doi:10.1111/ajt.13197 
18.  Perera MTPR, Mirza DF, Elias E. Liver transplantation: Issues for the next 20 
years. J Gastroenterol Hepatol. 2009;24 Suppl 3:S124-131. doi:10.1111/j.1440-
1746.2009.06081.x 
19.  Cauley RP, Vakili K, Fullington N, et al. Deceased-donor split-liver transplantation 
in adult recipients: is the learning curve over? J Am Coll Surg. 2013;217(4):672-
684.e1. doi:10.1016/j.jamcollsurg.2013.06.005 
20.  Hong JC, Yersiz H, Farmer DG, et al. Longterm outcomes for whole and segmental 
liver grafts in adult and pediatric liver transplant recipients: a 10-year comparative 
analysis of 2,988 cases. J Am Coll Surg. 2009;208(5):682-689; discusion 689-691. 
doi:10.1016/j.jamcollsurg.2009.01.023 
21.  Becker NS, Barshes NR, Aloia TA, et al. Analysis of recent pediatric orthotopic liver 
transplantation outcomes indicates that allograft type is no longer a predictor of 
survivals. Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant 
Soc. 2008;14(8):1125-1132. doi:10.1002/lt.21491 
22.  Massie AB, Kucirka LM, Kuricka LM, Segev DL. Big data in organ transplantation: 
registries and administrative claims. Am J Transplant Off J Am Soc Transplant Am 
Soc Transpl Surg. 2014;14(8):1723-1730. doi:10.1111/ajt.12777 
23.  Therneau T, Grambsch, P. Modeling Survival Data: Extending the Cox Model. New 
York: Springer; 2000. 
 93 
24.  Louis TA, Zeger SL. Effective communication of standard errors and confidence 
intervals. Biostat Oxf Engl. 2009;10(1):1-2. doi:10.1093/biostatistics/kxn014 
25.  Hsu EK, Shaffer ML, Gao L, et al. Analysis of Liver Offers to Pediatric Candidates 
on the Transplant Wait List. Gastroenterology. 2017;153(4):988-995. 
doi:10.1053/j.gastro.2017.06.053 
26.  Perito ER, Braun HJ, Dodge JL, Rhee S, Roberts JP. Justifying Nonstandard 
Exception Requests for Pediatric Liver Transplant Candidates: An Analysis of 
Narratives Submitted to the United Network for Organ Sharing, 2009-2014. Am J 
Transplant Off J Am Soc Transplant Am Soc Transpl Surg. 2017;17(8):2144-2154. 
doi:10.1111/ajt.14216 
27.  McDiarmid SV, Anand R, Martz K, Millis MJ, Mazariegos G. A multivariate analysis 
of pre-, peri-, and post-transplant factors affecting outcome after pediatric liver 
transplantation. Ann Surg. 2011;254(1):145-154. 
doi:10.1097/SLA.0b013e31821ad86a 
28.  Abt PL, Rapaport-Kelz R, Desai NM, et al. Survival among pediatric liver transplant 
recipients: impact of segmental grafts. Liver Transplant Off Publ Am Assoc Study 
Liver Dis Int Liver Transplant Soc. 2004;10(10):1287-1293. doi:10.1002/lt.20270 
29.  Roberts JP, Hulbert-Shearon TE, Merion RM, Wolfe RA, Port FK. Influence of graft 
type on outcomes after pediatric liver transplantation. Am J Transplant Off J Am 
Soc Transplant Am Soc Transpl Surg. 2004;4(3):373-377. 
30.  Cauley RP, Vakili K, Potanos K, et al. Deceased donor liver transplantation in 
infants and small children: are partial grafts riskier than whole organs? Liver 
Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc. 
2013;19(7):721-729. doi:10.1002/lt.23667 
31.  Goh A. An analysis of liver transplant survival rates from the UNOS registry. Clin 
Transpl. 2008:19-34. 
32.  Feng S, Goodrich NP, Bragg-Gresham JL, et al. Characteristics associated with 
liver graft failure: the concept of a donor risk index. Am J Transplant Off J Am Soc 
Transplant Am Soc Transpl Surg. 2006;6(4):783-790. doi:10.1111/j.1600-
6143.2006.01242.x 
33.  Avens Publishing Group - The Donor Risk Score: A Simpler Method to Grade Liver 
Allografts. http://www.avensonline.org/fulltextarticles/jsur-2332-4139-01-0012.html. 
Accessed October 2, 2017. 
34.  Mabrouk Mourad M, Liossis C, Kumar S, et al. Vasculobiliary complications 
following adult right lobe split liver transplantation from the perspective of 
reconstruction techniques. Liver Transplant Off Publ Am Assoc Study Liver Dis Int 
Liver Transplant Soc. 2015;21(1):63-71. doi:10.1002/lt.24015 
35.  Axelrod DA, Dzebisashvili N, Lentine KL, et al. Variation in biliary complication 
rates following liver transplantation: implications for cost and outcome. Am J 
 94 
Transplant Off J Am Soc Transplant Am Soc Transpl Surg. 2015;15(1):170-179. 
doi:10.1111/ajt.12970 
36.  Axelrod DA, Gheorghian A, Schnitzler MA, et al. The economic implications of 
broader sharing of liver allografts. Am J Transplant Off J Am Soc Transplant Am 
Soc Transpl Surg. 2011;11(4):798-807. doi:10.1111/j.1600-6143.2011.03443.x 
37.  Porter ME. What is value in health care? N Engl J Med. 2010;363(26):2477-2481. 
doi:10.1056/NEJMp1011024 
38.  Battula NR, Platto M, Anbarasan R, et al. Intention to Split Policy: A Successful 
Strategy in a Combined Pediatric and Adult Liver Transplant Center. Ann Surg. 
2017;265(5):1009-1015. doi:10.1097/SLA.0000000000001816 
39.  Barshes NR, Horwitz IB, Franzini L, Vierling JM, Goss JA. Waitlist mortality 
decreases with increased use of extended criteria donor liver grafts at adult liver 
transplant centers. Am J Transplant Off J Am Soc Transplant Am Soc Transpl 
Surg. 2007;7(5):1265-1270. doi:10.1111/j.1600-6143.2007.01758.x 
40.  Eren EA, Latchana N, Beal E, Hayes D, Whitson B, Black SM. Donations After 
Circulatory Death in Liver Transplant. Exp Clin Transplant Off J Middle East Soc 
Organ Transplant. 2016;14(5):463-470. 
41.  San Juan F, Cortes M. Mortality on the waiting list for liver transplantation: 
management and prioritization criteria. Transplant Proc. 2011;43(3):687-689. 
doi:10.1016/j.transproceed.2011.01.106 
42.  Data - OPTN. https://optn.transplant.hrsa.gov/data/. Accessed August 13, 2018. 
43.  Farmer DG, Venick RS, McDiarmid SV, et al. Predictors of outcomes after pediatric 
liver transplantation: an analysis of more than 800 cases performed at a single 
institution. J Am Coll Surg. 2007;204(5):904-914; discussion 914-916. 
doi:10.1016/j.jamcollsurg.2007.01.061 
44.  Nobel YR, Forde KA, Wood L, et al. Racial and ethnic disparities in access to and 
utilization of living donor liver transplants. Liver Transplant Off Publ Am Assoc 
Study Liver Dis Int Liver Transplant Soc. 2015;21(7):904-913. doi:10.1002/lt.24147 
45.  Amaral S, Patzer R. Disparities, race/ethnicity and access to pediatric kidney 
transplantation. Curr Opin Nephrol Hypertens. 2013;22(3):336-343. 
doi:10.1097/MNH.0b013e32835fe55b 
46.  Hsu EK, Shaffer M, Bradford M, Mayer-Hamblett N, Horslen S. Heterogeneity and 
disparities in the use of exception scores in pediatric liver allocation. Am J 
Transplant Off J Am Soc Transplant Am Soc Transpl Surg. 2015;15(2):436-444. 
doi:10.1111/ajt.13089 
47.  Shneider BL, Suchy FJ, Emre S. National and regional analysis of exceptions to the 
Pediatric End-Stage Liver Disease scoring system (2003-2004). Liver Transplant 
Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc. 2006;12(1):40-45. 
doi:10.1002/lt.20662 
 95 
48.  Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a 
Competing Risk. J Am Stat Assoc. 1999;94(446):496-509. 
doi:10.1080/01621459.1999.10474144 
49.  Massie AB, Desai NM, Montgomery RA, Singer AL, Segev DL. Improving 
distribution efficiency of hard-to-place deceased donor kidneys: Predicting 
probability of discard or delay. Am J Transplant Off J Am Soc Transplant Am Soc 
Transpl Surg. 2010;10(7):1613-1620. doi:10.1111/j.1600-6143.2010.03163.x 
50.  Salvalaggio PR, Neighbors K, Kelly S, et al. Regional variation and use of 
exception letters for cadaveric liver allocation in children with chronic liver disease. 
Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. 2005;5(8):1868-
1874. doi:10.1111/j.1600-6143.2005.00962.x 
51.  Utterson EC, Shepherd RW, Sokol RJ, et al. Biliary atresia: clinical profiles, risk 
factors, and outcomes of 755 patients listed for liver transplantation. J Pediatr. 
2005;147(2):180-185. doi:10.1016/j.jpeds.2005.04.073 
52.  Shneider BL, Brown MB, Haber B, et al. A multicenter study of the outcome of 
biliary atresia in the United States, 1997 to 2000. J Pediatr. 2006;148(4):467-474. 
doi:10.1016/j.jpeds.2005.12.054 
53.  Reid AE, Resnick M, Chang Y, Buerstatte N, Weissman JS. Disparity in use of 
orthotopic liver transplantation among blacks and whites. Liver Transplant Off Publ 
Am Assoc Study Liver Dis Int Liver Transplant Soc. 2004;10(7):834-841. 
doi:10.1002/lt.20174 
54.  Moylan CA, Brady CW, Johnson JL, Smith AD, Tuttle-Newhall JE, Muir AJ. 
Disparities in liver transplantation before and after introduction of the MELD score. 
JAMA. 2008;300(20):2371-2378. doi:10.1001/jama.2008.720 
55.  Sharma P, Schaubel DE, Messersmith EE, Guidinger MK, Merion RM. Factors that 
affect deceased donor liver transplantation rates in the United States in addition to 
the Model for End-stage Liver Disease score. Liver Transplant Off Publ Am Assoc 
Study Liver Dis Int Liver Transplant Soc. 2012;18(12):1456-1463. 
doi:10.1002/lt.23548 
56.  Shilling LM, Norman ML, Chavin KD, et al. Healthcare professionals’ perceptions of 
the barriers to living donor kidney transplantation among African Americans. J Natl 
Med Assoc. 2006;98(6):834-840. 
57.  Gore JL, Danovitch GM, Litwin MS, Pham P-TT, Singer JS. Disparities in the 
utilization of live donor renal transplantation. Am J Transplant Off J Am Soc 
Transplant Am Soc Transpl Surg. 2009;9(5):1124-1133. doi:10.1111/j.1600-
6143.2009.02620.x 
58.  Karnsakul W, Intihar P, Konewko R, et al. Living donor liver transplantation in 
children: a single North American center experience over two decades. Pediatr 
Transplant. 2012;16(5):486-495. doi:10.1111/j.1399-3046.2012.01725.x 
 96 
59.  Mogul DB, Luo X, Bowring MG, et al. Fifteen-Year Trends in Pediatric Liver 
Transplants: Split, Whole Deceased, and Living Donor Grafts. J Pediatr. 
2018;196:148-153.e2. doi:10.1016/j.jpeds.2017.11.015 
60.  Kim WR, Stock PG, Smith JM, et al. OPTN/SRTR 2011 Annual Data Report: liver. 
Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. 2013;13 Suppl 
1:73-102. doi:10.1111/ajt.12021 
61.  Purnell TS, Hall YN, Boulware LE. Understanding and overcoming barriers to living 
kidney donation among racial and ethnic minorities in the United States. Adv 
Chronic Kidney Dis. 2012;19(4):244-251. doi:10.1053/j.ackd.2012.01.008 
62.  Waterman AD, Peipert JD, Hyland SS, McCabe MS, Schenk EA, Liu J. Modifiable 
patient characteristics and racial disparities in evaluation completion and living 
donor transplant. Clin J Am Soc Nephrol CJASN. 2013;8(6):995-1002. 
doi:10.2215/CJN.08880812 
63.  Wachterman MW, McCarthy EP, Marcantonio ER, Ersek M. Mistrust, 
misperceptions, and miscommunication: a qualitative study of preferences about 
kidney transplantation among African Americans. Transplant Proc. 2015;47(2):240-
246. doi:10.1016/j.transproceed.2015.01.016 
64.  Rodrigue JR, Cornell DL, Kaplan B, Howard RJ. Patients’ willingness to talk to 
others about living kidney donation. Prog Transplant Aliso Viejo Calif. 
2008;18(1):25-31. 
65.  Traino HM, West SM, Nonterah CW, Russell J, Yuen E. Communicating About 
Choices in Transplantation (COACH). Prog Transplant Aliso Viejo Calif. 
2017;27(1):31-38. doi:10.1177/1526924816679844 
66.  Boulware LE, Meoni LA, Fink NE, et al. Preferences, knowledge, communication 
and patient-physician discussion of living kidney transplantation in African 
American families. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. 
2005;5(6):1503-1512. doi:10.1111/j.1600-6143.2005.00860.x 
67.  DiMartini A, Dew MA, Liu Q, et al. Social and Financial Outcomes of Living Liver 
Donation: A Prospective Investigation Within the Adult-to-Adult Living Donor Liver 
Transplantation Cohort Study 2 (A2ALL-2). Am J Transplant Off J Am Soc 
Transplant Am Soc Transpl Surg. 2017;17(4):1081-1096. doi:10.1111/ajt.14055 
68.  Habbous S, Sarma S, Barnieh LJ, et al. Healthcare Costs for the Evaluation, 
Surgery, and Follow-Up Care of Living Kidney Donors. Transplantation. 
2018;102(8):1367-1374. doi:10.1097/TP.0000000000002222 
69.  Dew MA, Jacobs CL. Psychosocial and socioeconomic issues facing the living 
kidney donor. Adv Chronic Kidney Dis. 2012;19(4):237-243. 
doi:10.1053/j.ackd.2012.04.006 
70.  Rodrigue JR, Kazley AS, Mandelbrot DA, et al. Living Donor Kidney 
Transplantation: Overcoming Disparities in Live Kidney Donation in the US--
 97 
Recommendations from a Consensus Conference. Clin J Am Soc Nephrol CJASN. 
2015;10(9):1687-1695. doi:10.2215/CJN.00700115 
71.  Arnon R, Annunziato RA, Willis A, et al. Liver transplantation for children with biliary 
atresia in the pediatric end-stage liver disease era: the role of insurance status. 
Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc. 
2013;19(5):543-550. doi:10.1002/lt.23607 
72.  Mogul DB, Luo X, Chow EK, et al. Impact of Race and Ethnicity on Outcomes for 
Children Waitlisted for Pediatric Liver Transplantation. J Pediatr Gastroenterol Nutr. 
2018;66(3):436-441. doi:10.1097/MPG.0000000000001793 
73.  Thammana RV, Knechtle SJ, Romero R, Heffron TG, Daniels CT, Patzer RE. 
Racial and socioeconomic disparities in pediatric and young adult liver transplant 
outcomes. Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant 
Soc. 2014;20(1):100-115. doi:10.1002/lt.23769 
74.  Mathur AK, Schaubel DE, Gong Q, Guidinger MK, Merion RM. Racial and ethnic 
disparities in access to liver transplantation. Liver Transplant Off Publ Am Assoc 
Study Liver Dis Int Liver Transplant Soc. 2010;16(9):1033-1040. 
doi:10.1002/lt.22108 
75.  Mathur AK, Ashby VB, Fuller DS, et al. Variation in access to the liver transplant 
waiting list in the United States. Transplantation. 2014;98(1):94-99. 
doi:10.1097/01.TP.0000443223.89831.85 
76.  Mogul DB, Henderson ML, Bridges JFP. Expanding the Facebook Platform to 
Engage and Educate Online Communities. Am J Gastroenterol. 2018;113(4):457-
458. doi:10.1038/ajg.2017.450 
77.  Kim PTW, Testa G. Living donor liver transplantation in the USA. Hepatobiliary 
Surg Nutr. 2016;5(2):133-140. doi:10.3978/j.issn.2304-3881.2015.06.01 
78.  DEPARTMENT OF HEALTH & HUMAN SERVICES. :110. 
79.  Ross K, Patzer RE, Goldberg DS, Lynch RJ. Sociodemographic Determinants of 
Waitlist and Posttransplant Survival Among End-Stage Liver Disease Patients. Am 
J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. 2017;17(11):2879-
2889. doi:10.1111/ajt.14421 
80.  Doyle A, Rabie RN, Mokhtari A, et al. Recipient factors associated with having a 
potential living donor for liver transplantation. Liver Transplant Off Publ Am Assoc 
Study Liver Dis Int Liver Transplant Soc. 2015;21(7):897-903. doi:10.1002/lt.24148 
81.  Purnell TS, Luo X, Cooper LA, et al. Association of Race and Ethnicity With Live 
Donor Kidney Transplantation in the United States From 1995 to 2014. JAMA. 
2018;319(1):49-61. doi:10.1001/jama.2017.19152 
82.  Nobel YR, Forde KA, Wood L, et al. Racial and ethnic disparities in access to and 
utilization of living donor liver transplants. Liver Transplant Off Publ Am Assoc 
Study Liver Dis Int Liver Transplant Soc. 2015;21(7):904-913. doi:10.1002/lt.24147 
 98 
83.  NW 1615 L. St, Washington S 800, Inquiries D 20036 U-419-4300 | M-419-4372 | 
M. Social Media Fact Sheet. Pew Res Cent Internet Sci Tech. February 2018. 
http://www.pewinternet.org/fact-sheet/social-media/. Accessed September 11, 
2018. 
84.  PricewaterhouseCoopers. Social media “likes” healthcare: From marketing to social 
business. PwC. https://www.pwc.com/us/en/health-industries/health-research-
institute/publications/health-care-social-media.html. Accessed September 11, 2018. 
85.  Mitchell SJ, Godoy L, Shabazz K, Horn IB. Internet and mobile technology use 
among urban African American parents: survey study of a clinical population. J Med 
Internet Res. 2014;16(1):e9. doi:10.2196/jmir.2673 
86.  Melloul E, Raptis DA, Oberkofler CE, Dutkowski P, Lesurtel M, Clavien P-A. Donor 
information for living donor liver transplantation: where can comprehensive 
information be found? Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver 
Transplant Soc. 2012;18(8):892-900. doi:10.1002/lt.23442 
87.  Escobedo W, Weismuller P. Assessing health literacy in renal failure and kidney 
transplant patients. Prog Transplant Aliso Viejo Calif. 2013;23(1):47-54. 
doi:10.7182/pit2013473 
88.  Warsame F, Haugen CE, Ying H, et al. Limited Health Literacy and Adverse 
Outcomes Among Kidney Transplant Candidates. Am J Transplant Off J Am Soc 
Transplant Am Soc Transpl Surg. July 2018. doi:10.1111/ajt.14994 
89.  Li T, Dokus MK, Kelly KN, et al. Survey of Living Organ Donors’ Experience and 
Directions for Process Improvement. Prog Transplant Aliso Viejo Calif. 
2017;27(3):232-239. doi:10.1177/1526924817715467 
90.  Kucirka LM, Purnell TS, Segev DL. Improving Access to Kidney Transplantation: 
Referral Is Not Enough. JAMA. 2015;314(6):565-567. doi:10.1001/jama.2015.8932 
91.  Rodrigue JR, Paek MJ, Egbuna O, et al. Making house calls increases living donor 
inquiries and evaluations for blacks on the kidney transplant waiting list. 
Transplantation. 2014;98(9):979-986. doi:10.1097/TP.0000000000000165 
92.  Doyle MBM, Maynard E, Lin Y, et al. Outcomes with split liver transplantation are 
equivalent to those with whole organ transplantation. J Am Coll Surg. 
2013;217(1):102-112; discussion 113-114. doi:10.1016/j.jamcollsurg.2013.03.003 
93.  Segev DL, Maley WR, Simpkins CE, et al. Minimizing risk associated with elderly 
liver donors by matching to preferred recipients. Hepatol Baltim Md. 
2007;46(6):1907-1918. doi:10.1002/hep.21888 
94.  McDiarmid SV, Anand R, Lindblad AS, Principal Investigators and Institutions of the 
Studies of Pediatric Liver Transplantation (SPLIT) Research Group. Development 
of a pediatric end-stage liver disease score to predict poor outcome in children 
awaiting liver transplantation. Transplantation. 2002;74(2):173-181. 
 99 
95.  Institute of Medicine, Committee on Organ Procurement and Transplantation 
Policy, Division of Health Sciences Policy. Organ Procurement and 
Transplantation: Assessing Current Policies and the Potential Impact of the DHHS 
Final Rule. National Academies Press. DC; 1999. https://doi.org/10.17226/9628. 
96.  Perito ER, Roll G, Dodge JL, Rhee S, Roberts JP. Split liver transplantation and 
pediatric waitlist mortality in the United States: potential for improvement. 
Transplantation. April 2018. doi:10.1097/TP.0000000000002249 
97.  Hatch O. S.2048 - 98th Congress (1983-1984): National Organ Transplant Act. 
https://www.congress.gov/bill/98th-congress/senate-bill/2048. Published October 











Start of Block: Choice tasks 
 
Q1 Living-Donor Liver Transplantation Survey   
 Thank you for taking the time to complete our survey.  Your answers are very important 
to us. This survey is for research purposes only. The answers are anonymous and will be 
kept strictly confidential. Your participation is completely voluntary and will not 
influence your treatment. You can stop at any time if you no longer want to participate 
in this research study.     
THIS BRIEF SURVEY SHOULD ONLY BE COMPLETED BY PARENTS OF CHILDREN WITH 
LIVER DISEASE  ESTIMATED TIME REQUIRED: 5-10 MINUTES     This is a survey about 
Living-donor Liver Transplantation, the process by which a part of a healthy liver is 
transplanted from a living person into another person with advanced liver disease.  We 
are interested in understanding what you know and think about living-donor liver 
transplantation.  While you can discuss this survey with other people, it is important 
that you give us your opinion and not someone else’s opinion. 
PLEASE ONLY COMPLETE THIS SURVEY ONE TIME     This study is being conducted by Dr. 
Douglas Mogul, Assistant Professor of Pediatric Gastroenterology and Hepatology at 
Johns Hopkins University and was approved by the Institutional Review Board at Johns 
Hopkins University (protocol #00096438).  
 
 




Q2 Has your child had a liver transplant? 
o Yes, my child has had a liver transplant  (1)  
o No, but my child is currently on the waitlist for a liver transplant  (2)  
o No, but my child is currently being evaluated for a liver transplant  (5)  
o No, and my child is not currently being evaluated (considered) for a liver transplant  (3)  
o No, and I am not sure whether my child is currently on the waitlist for a liver transplant  
(4)  
o Other  (6)  
 
Skip To: Q4 If Has your child had a liver transplant? = Yes, my child <strong>has had </strong>a liver 
transplant 
Skip To: Q4 If Has your child had a liver transplant? = No, but my child is currently <strong>on the 
waitlist</strong> for a liver transplant 
Skip To: Q4 If Has your child had a liver transplant? = No, but my child is currently <strong>being evaluated 
</strong>for a liver transplant 
 
 
Q3 Thank you for your consideration. There is no need to answer any additional 
questions.  
 
Skip To: End of Survey If Thank you for your consideration. There is no need to answer any additional 
questions. () Is Displayed 
 




Q30 My child's transplant center performs living-donor liver transplantation for children 
o Yes  (1)  
o No  (2)  





Q4 These questions ask about your knowledge of living-donor liver 
transplantation. Please indicate whether you: strongly agree; agree; neither agree nor 











donate a part 
of their liver to 
a patient with 
liver disease. 
(1)  









process. (2)  
o  o  o  o  o  
The cost of 
healthcare for 





are covered by 
the recipient's 
health 
insurance. (3)  
o  o  o  o  o  
I know what all 
the necessary 






o  o  o  o  o  
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I know who to 






o  o  o  o  o  
Based on 
discussions 
with my child's 
doctor, I feel 
well-informed 
about living 
donation (6)  





Q5 Based on discussion with my child's doctor/surgeon, including options such as living 
donation and deceased donation, I felt that: 
o living donation is a better option compared to deceased donation  (1)  
o living donation and deceased donation are equally good options  (4)  
o living donation is a worse option compared to deceased donation  (2)  
o I have/had no opinion about which option is better  (3)  
 
 




Q6 How comfortable are you (or were you) with the idea of trying to donate a part of 
your liver to your child? 
o Very comfortable  (1)  
o Somewhat comfortable  (2)  
o Neutral  (3)  
o Somewhat uncomfortable  (4)  
o Very uncomfortable  (6)  
o I have been told by a doctor that I am not eligible to donate  (7)  
 
 





Thinking about your social circle, how many people do you know that you would (or 
did) feel comfortable asking to be a living donor for your child? 
o 0  (1)  
o 1  (2)  
o 2  (3)  
o 3  (4)  




Q8 Please rate the following question: If I ask a friend or family member to consider 
being a living donor, it may cause problems or stress in our relationship.   
o Strongly disagree  (25)  
o Somewhat disagree  (26)  
o Neither agree nor disagree  (27)  
o Somewhat agree  (28)  





Q9 Looking back over the last year, how many people did you talk to about important 
health-related things in your life, such as important health concerns, achieving an 
important milestone, or health problems you or your family are having? 
o 0  (1)  
o 1  (2)  
o 2  (3)  
o 3  (4)  
o 4 or more  (5)  
 
 




Q10 These questions ask about your relationship with your child’s liver doctor.  Please 
indicate whether you: strongly agree; agree; neither agree nor disagree (neutral); 









me. (1)  o  o  o  o  o  
I like my 
child’s doctor.  
(2)  o  o  o  o  o  
I trust my 
child’s doctor 
to do the 
right things 
for my child 
and my child. 
(3)  







plan for my 
child. (4)  










process. (5)  








Q11 Some parents may have concerns about how a living-donor liver transplant will 
affect their child and family.   
   
With respect to living-donor liver transplantation, rate the extent to which you feel 



















child).  (1)  






child). (2)  




and amount of 
time off 
required to 








ability to take 
care of your 
family. (4)  






Q12 Some parents may have concerns about how a living-donor liver donation will 
affect the donor.      With respect to living-donor liver transplantation, rate the extent 

















for the donor.  
(1)  





the donor. (2)  




and amount of 
time off 
required. (3)  




to take care of 
family. (4)  




Page Break  
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End of Block: Choice tasks 
 
Start of Block: Background information 
 
 
Q13 Background Information About You 
  











Q15 What is your (i.e., the parent) gender? 
o Female  (1)  
o Male  (2)  




Q32 Is your child's transplant center in the United States 
o Yes  (1)  
o No  (2)  
 




Q31 In which state is your child's transplant center 




Q16 What race/ethnic groups best describes you? (Please check all that apply) 
▢ White  (1)  
▢ Black or African-American  (2)  
▢ American Indian or Alaskan Native  (3)  
▢ Asian or Pacific Islander  (4)  
▢ Hispanic  (5)  




Q17 Which of the following devices do you currently own?  (Please check all that 
apply) 
▢ Desktop computer    (1)  
▢ Laptop computer         (2)  
▢ Tablet device (such as iPad, Kindle Fire, Samsung Galaxy Note, etc.)  (3)  
▢ Cell phone WITH internet capabilities (such as iPhone, Samsung Galaxy, Android, 





Q18 How often do you use your computer, tablet, or cellphone to access the internet? 
o Less than 60 minutes a day    (1)  
o 1-4 hours a day  (2)  
o 5-8 hours a day  (3)  




Q19 What is your marital status? 
o Married/living with a partner  (1)  
o Widowed  (2)  
o Divorced  (3)  
o Separated  (4)  





Q20 What is your current employment status? 
o Employed full-time  (1)  
o Employed part-time  (2)  
o Retired  (3)  
o Disabled  (4)  
o Homemaker  (5)  
o Student  (6)  
o Unemployed  (7)  




Q21 Are you the primary breadwinner for your household? 
o Yes  (1)  
o No  (2)  




Q22 Including yourself, how many working adults are in your household? 
o 0  (1)  
o 1  (2)  
o 2  (3)  





Q23 What is the highest level of school you (the parent) have completed or the 
highest degree you have received? 
o Less than high school degree  (1)  
o High school degree or equivalent (e.g. GED)  (2)  
o Some college or vocational/technical degree  (3)  
o College or vocational/technical degree  (4)  




Q24 Are you CURRENTLY covered by any of the following types of health insurance or 
health coverage plans?  (Mark ‘yes’ or ‘no’ for EACH type of coverage listed below) 
 Yes (1) No (2) Don’t Know (3) 
Private insurance (1)  o  o  o  
Medicaid (i.e., state 
medical assistance) 
(2)  o  o  o  
Medicare (for people 
over 65 years) (3)  o  o  o  
Other type of health 
insurance  (e.g. Indian 
Health Service, 
TRICARE, VA, or other 
military health care) 
(4)  






Q25 In general, how would you (the parent) rate your overall health? 
o Poor  (1)  
o Fair  (2)  
o Good  (3)  
o Very good  (4)  




Q26 Please select the severity level that best describes your child’s liver disease.   
o Mild: my child can perform most routine daily activities (e.g., school or daycare), and his 
or her life is not disrupted by the liver disease  (1)  
o Moderate: my child can perform most daily activities, but he or she is not able to do 
everything because of the liver disease  (2)  
o Severe: my child is not able to perform most activities that other children are able to, 
although they are rarely in the hospital  (3)  
o Life-threatening: my child is often in the hospital as a result of the liver disease.  (4)  
 
 




Q27 Thank you very much for your time! 
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States and Canada. J Pediatr. 2015 Dec; 167(6); 1287-1294. 
9. Wang KS, Section on Surgery for the Committee in Fetus and Newborn. Newborn 
Screening for Biliary Atresia. Pediatrics. 2015 Dec; 136(6):e1663-9. 
10. Schwarz KB, Cloonan YK, Ling SC, et al. Children with Chronic Hepatitis B in the 
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11. Wang KS, Tiao G, Bass LM, Hertel PM, Mogul D, et al. Analysis of surgical 
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Hepatology. 2016 May;65(5):1645-165. 
12. Mogul D, Nakamura Y, Seo J, Blauvelt B, Bridges JF. The Unknown Burden and 
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Apr;17(2):181-188.  
13. Mogul D, Nagy P, Bridges JFP. Building Stronger Online Communities Through the 
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28.  
14. Mogul D, Luo X, Chow E, Massie A, et al. Impact of Race and Ethnicity on 
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Gastoenterol Nutr. Epub Nov,  2017.  
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Inventions, Patents, Copyrights (pending, awarded) 
 
Date Title 
2013 PoopMD: mobile app to evaluate acholic stools and gastrointestinal 
bleeding for Apple, Android and web-based platforms 
2014 Liver Space: mobile app to educate and increase social engagement 








2015- Improving pediatric liver transplant allocation. NIH/AHRQ. 
1K08HS023876-01. $729,875. PI: Douglas Mogul. 75% effort.   
2017 Immunologic and virologic correlates of the age-related decrease in 
HBV DNA in Children. NIDDK. 5U01DK082916-10. PI: Kathleen 
Schwarz. 5% effort. 
  
Previous  
2015-2017 Development of Liver Space, an app for individuals with pediatric liver 
disease. Gilead Foundation. $100,000. PI: Douglas Mogul.  
2015-2017 Integration of Apple ResearchKit and a content management system 
for PoopMD. Pershing Square Foundation. $41,000 PI: Douglas Mogul.  
2010-2015 Effect of HBA DNA Methylation and the Mutant 1762T / 1764A on Viral 
Load & HCC HBV Clinical Research Network. NIDDK. U01DK 082916-
01 $2,520,427 PI: Kathleen Schwarz, MD; Co-Investigator 6% effort 
2011-2013 Epigenetic Regulation of Hepatitis B Virus, American College of 
Gastroenterology Clinical Research Award, $30,250 (research only); 
PI: Douglas Mogul, MD MPH 
2011-2012 T32 National Research Service Award, NIIH. $47,000; PI: George 
Dover, MD JHU Dept of Pediatrics; Trainee recipient – 80% effort  
 




 2018 Developing a digital tool to improve transition readiness for pediatric 
liver transplant recipients: a multi-stakeholder approach. Department of 




2013-2015 HCB Health, Austin, TX: Health marketing firm to develop mobile app to 
evaluate acholic stools and gastrointestinal bleeding for Apple, Android 
and web-based platforms; update stool color information on CMSC 
website. 
2013- Procter & Gamble, Cincinnati, OH: Manufacturer of PampersTM, which 
is distributed to ~95% of nurseries in the U.S. Company, will distribute 
stool color card to nurseries and direct patients to CMSC website for 
more information. Company will provide link to CMSC website to 3 
million subscribers of their digital content, and to PoopMD in the Apple 
and Android store. 
2014-2015 iHealthVentures, New Jersey: Developer of mobile health apps. Will 
develop Liver Space, mobile app to educate and socially engage 
children with liver disease, and provide a means to conduct survey 
research in these diseases.  
2015-2016 Beneufit, San Francisco, CA: Developer of mobile health applications 
and expert in Apple ResearchKit. Company will update PoopMD 





Educational Publications  
 
Invited Review Articles 
1. Mogul D, Torbenson M, Schwarz. Epigenetic Regulation of Hepatitis B Virus. Current 
Hepatitis Reports. Sep 2011; 10:277-84. 
2. Mogul D, Schwarz K. Managing HCV-infected children. Clinical Liver Diseases. Sep 
2012; 1(3): 77-80.  
3. Mogul D, Ng K. Pediatric Liver Tumors. Clinics in Liver Disease. In press. 
 
Book Chapters 
1. Mogul D, Sibley E. Congenital Disorders of Digestion and Absorption, In: Diarrhea: 
Diagnostic and Therapeutic Advances.  Guandalini S, Vaziri H, Eds. New York: 
Springer. pp. 159-176. 2010. 
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2. Mogul D, Schwarz K. What is the correct management and follow up for infants 
whose mothers are infected with Hepatitis B? In: Bousvaros A, Rosh J. Curbside 
Consultation in Pediatric GI. SLACK Inc. 2013. 
3. Laroche G, Mogul D. Biliary atresia. 5 minute Pediatric Consult, 7th ed. Wolters 
Kluwer. New York. 2015. 
4. Ogholikhan S, Mogul D. Biliary atresia. 5 minute Pediatric Consult, 8th ed. Wolters 
Kluwer. New York. In press. 
 
Other Media 
1. Videotaped for Fox45 News segment on PoopMD. June 29, 2014. 





11/3/17 “Meet the professors breakfast” on Using social media for research, 
North American Society for Pediatric Gastroenterology, Hepatology, 
and Nutrition annual meeting, Las Vegas, NV. 
10/23/2017 “Meet the professors breakfast” on Neonatal cholestasis, American 
Association of the Study of Liver Diseases annual meeting, 
Washington, DC. 
10/10/2015 “Meet the professors breakfast” on Hepatitis B virus, North American 
Society for Pediatric Gastroenterology, Hepatology, and Nutrition, 
annual meeting, Washington, DC.  
7/30/2014 Lectures on acute liver failure and gastrointestinal bleeding to PICU 
fellows. Bloomberg Children’s Center. 
8/1/2013 Lectures on acute liver failure and gastrointestinal bleeding to PICU 
fellows. Bloomberg Children’s Center. 
4/13/2013 Lecture on gallstone and cholecystitis as part of Pediatric Trends. 
Turner Auditorium. 
2/27/2013 Lecture on gastrointestinal reflux to medical students. Bloomberg 
Children’s Center. 
8/7/2012 Lectures on acute liver failure and gastrointestinal bleeding to PICU 





Date Responsibility Current Position 
2013 Grace Felix, pediatric resident, for project on biliary 
atresia stool card. 
Senior fellow 
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2013 Stephanie Honigbaum, fellow in pediatric 
gastroenterology, for project on biliary atresia stool 
card. 
Private practice 
2013 Anna Schuettge, nurse practitioner student, for project 
on biliary atresia stool card. 




Amy Franciscovich, pediatric resident, for research on 
PoopMD, an app to screen infants with biliary atresia. 





Sina Ogholikhan, pediatric GI fellow, multiple projects 
related to biliary atresia. 
Private practice 
2017- Karina Covarrubias, medical student, project on length 








2009 Board Certified in General Pediatrics, American Board of Pediatrics 






2008 California Medical Board 






2012- Attending, Pediatric Gastroenterology, Nutrition and Hepatology 
Division, the Johns Hopkins University School of Medicine, Baltimore, 
MD.  Floor rounds, outpatient clinics, multidisciplinary conferences, 
didactic rounds, procedures. Perform and train post-doctoral fellows in 
pediatric gastroenterology procedures. 
2017- Medical Director, Pediatric Liver Transplantation. Floor rounds and 
outpatient clinics, multidisciplinary conferences, didactic rounds and 
procedures. Also oversee pediatric liver and liver transplantation rounds 
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with liver and liver transplant nurse practitioners, post-doctoral fellows 








2009 North American Society of Pediatric Gastroenterology, Hepatology and 
Nutrition Inflammatory Bowel Disease Committee, North American 
Society of Pediatric Gastroenterology, Hepatology, and Nutrition 
2011 American Association for the Study of Liver Diseases  
2014-2017 Technology Committee, North American Society of Pediatric 
Gastroenterology, Hepatology, and Nutrition 
2014-2015 Clinical and Public Policy Committee, American Association for the 
Study of Liver Diseases  
2016- Communications and Technology Committee, American Association for 









2007 Teaching and Tomorrow Program, North American Society of Pediatric 
Gastroenterology, Hepatology, and Nutrition, Salt Lake City, UT.  
2009 Resident Teacher Award, Lucile Packard Children’s Hospital of 
Stanford University, Palo Alto, CA. 
2014 Young Faculty Clinical Research Award, North American Society of 
Pediatric Gastroenterology, Hepatology, and Nutrition, Atlanta, GA  
2017 Nomination for Excellence in Service and Professionalism Award, 






May, 2015 PoopMD: A mobile health application, accurately identifies perinatal 
alcoholic stools. Pediatric Grand Rounds, Johns Hopkins University.  
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Feb, 2017 Liver Space: A Facebook Health Application to Strengthen Online 
Communities. Bioinformatics Grand Rounds, Johns Hopkins University. 
May, 2017 Using social media to improve outcomes in pediatric liver disease. 








Dr. Douglas Mogul was born on August 30, 1976 at New York Hospital and lived 
throughout his childhood in Chappaqua, NY. After graduating from Horace 
Greely High School in 1994, he studied biochemistry and modern European 
history at Bowdoin College in Brunswick, ME where he graduated magna cum 
laude in 1998. After college, he earned a Masters in Public Health at the 
University of California, Berkeley where he concentrated his studies in the 
epidemiology of infectious disease including tropical medicine and hepatitis C 
virus. After graduate school, he lived in Salvador de Bahia, Brazil, where he 
researched schistosomiasis in a rural community. He attended the Albert Einstein 
College of Medicine at Yeshiva University. After completing his pre-clinical third 
year, he was accepted into the Clinical Research Training Program of the 
National Institutes of Health, where he worked for one year under Dr. Daniel 
Kastner studying periodic fever syndromes. Dr. Mogul graduated from medical 
school in 2006 and completed internship and residency at the Lucile Packard 
Children’s Hospital of Stanford University. He completed his clinical training as a 
fellow in pediatric gastroenterology, hepatology and nutrition at the Johns 
Hopkins University School of Medicine in 2009. Since that time, he has been an 
Assistant Professor of Pediatrics at Johns Hopkins. 
 
Dr. Mogul’s research is focused on three main areas. First, he was awarded an 
NIH training grant to study ways to improve outcomes for children with end-stage 
liver disease under the mentorship of Dr. Dorry Segev and Dr. John Bridges. This 
 128 
research has been presented at national meetings including as a plenary and 
has yielded several publications. He has also received grants from the Gilead 
Foundation as well as a Johns Hopkins Innovation award to create digital tools 
that help patients and families with liver disease. One tool, PoopMD, has been 
chosen as a top app for parents of newborn babies by several organizations 
including YahooHealth News and Huffington Post. Finally, he is a member of the 
NIH Hepatitis B Research network through which he conducts studies of children 
with hepatitis B, and he participates in clinical trials of viral hepatitis.  
 
 
 
